Section Editor: Peter S. A. Glass

Dexamethasone to Prevent Postoperative Nausea and Vomiting: An Updated Meta-Analysis of Randomized Controlled Trials

Gildasio S. De Oliveira Jr., MD, MSCI, Lucas J. Santana Castro-Alves, MD, Shireen Ahmad, MD, Mark C. Kendall, MD, and Robert J. McCarthy, PharmD

BACKGROUND: Dexamethasone has an established role in decreasing postoperative nausea and vomiting (PONV); however, the optimal dexamethasone dose for reducing PONV when it is used as a single or combination prophylactic strategy has not been clearly defined. In this study, we evaluated the use of 4 mg to 5 mg and 8 mg to 10 mg IV doses of dexamethasone to prevent PONV when used as a single drug or as part of a combination preventive therapy.

METHODS: A wide search was performed to identify randomized clinical trials that evaluated systemic dexamethasone as a prophylactic drug to reduce postoperative nausea and/or vomiting. The effects of dexamethasone dose were evaluated by pooling studies into 2 groups: 4 mg to 5 mg and 8 mg to 10 mg. The first group represents the suggested dexamethasone dose to prevent PONV by the Society for Ambulatory Anesthesia (SAMBA) guidelines, and the second group represents twice the dose range recommended by the guidelines. The SAMBA guidelines were developed in response to studies, which have been performed to examine different dosages of dexamethasone.

RESULTS: Sixty randomized clinical trials with 6696 subjects were included. The 4-mg to 5-mg dose dexamethasone group experienced reduced 24-hour PONV compared with control, odds ratio (OR, 0.31; 95% confidence interval [CI], 0.23–0.41), and number needed to treat (NNT, 3.7; 95% CI, 3.0–4.7). When used together with a second antiemetic, the 4-mg to 5-mg dexamethasone group also experienced reduced 24-hour PONV compared with control (OR, 0.50; 95% CI, 0.35– 0.72; NNT, 6.6; 95% CI, 4.3–12.8). The 8-mg to 10-mg dose dexamethasone group experienced decreased 24-hour PONV compared with control (OR, 0.26; 95% CI, 0.20–0.32; NNT, 3.8; 95% Cl, 3.0-4.3). Asymmetric funnel plots were observed in the 8-mg to 10-mg dose analysis, suggesting the possibility of publication bias. When used together with a second antiemetic, the 8-mg to 10-mg dose group also experienced reduced incidence of 24-hour PONV (OR, 0.35; 95%) CI, 0.22–0.53; NNT, 6.2; 95% CI, 4.5–10). In studies that provided a direct comparison between groups, there was no clinical advantage of the 8-mg to 10-mg dexamethasone dose compared with the 4-mg to 5-mg dose on the incidence of postoperative nausea and/or vomiting. CONCLUSIONS: Our results showed that a 4-mg to 5-mg dose of dexamethasone seems to have similar clinical effects in the reduction of PONV as the 8-mg to 10-mg dose when dexamethasone was used as a single drug or as a combination therapy. These findings support the current recommendation of the SAMBA guidelines for PONV, which favors the 4-mg to 5-mg dose regimen of systemic dexamethasone. (Anesth Analg 2013;116:58–74)

examethasone is a corticosteroid antiinflammatory drug with an established role for the prevention of postoperative nausea and vomiting (PONV). The Society for Ambulatory Anesthesia (SAMBA) guidelines for the management of PONV recommends a prophylactic dose of 4 mg to 5 mg for patients at high risk of PONV regardless of the surgical procedure.¹ A previous systematic review, evaluating patients undergoing various surgical procedures, did not address the effect of varying doses of dexamethasone on PONV.² Using a meta-analysis, Karanicolas et al.³ evaluated patients undergoing laparoscopic cholecystectomy and suggested a greater efficacy to reduce PONV from a systemic dose of dexamethasone 8 mg to 16 mg compared with 2 mg to 5 mg. The generalizability of these findings to patients undergoing other surgical procedures has not been established. It also remains unclear whether varying doses of dexamethasone may have different efficacy when administered alone or in conjunction with other antiemetic drugs.

The primary objective of this study was to examine the effects of 4 mg to 5 mg and 8 mg to 10 mg single dose systemic dexamethasone on the incidence of PONV. A secondary objective was to evaluate whether the effect changed when dexamethasone was administered alone or in a combination regimen with another antiemetic drug.

From the Department of Anesthesiology, Northwestern University, Chicago, Illinois.

Accepted for publication July 31, 2012.

Funded by the Department of Anesthesiology, Northwestern University. The authors declare no conflicts of interest.

Reprints will not be available from the authors.

Address correspondence to Gildasio S. De Oliveira Jr., MD, MSCI, Department of Anesthesiology, Northwestern Memorial Hospital, 251 E Huron St, F5-704, Chicago, IL 60611. Address e-mail to G-jr@northwestern.edu.

Copyright © 2012 International Anesthesia Research Society DOI: 10.1213/ANE.0b013e31826f0a0a

METHODS

This quantitative systematic review was conducted following the guidelines of the PRISMA statement.⁴

Systematic Search

Published reports of randomized trials evaluating the effects of dexamethasone on postoperative nausea and/ or vomiting were searched using the National Library of Medicine's PubMed database, EMBASE, the Cochrane Database of Systematic Reviews, and Google Scholar inclusive to October 1, 2011. The initial search was performed using the free-text and MeSH terms "dexamethasone." The "and" function was used to combine the initial search with the MeSH terms "postoperative" and "nausea." No language restriction was used. The search was then limited to randomized controlled clinical trials in subjects older than 18 years. An attempt to identify additional studies not found by the primary search methods was performed by reviewing the reference lists from identified studies. No search was performed for unpublished studies. This initial search yielded 163 randomized clinical trials.

Selection of Included Studies

The study's inclusion and exclusion criteria were determined before the systematic search. Two authors (GDO and LJCA) independently evaluated the abstracts and results of the 163 articles obtained by the initial search. Seventy-four articles that were clearly not relevant based on our inclusion and exclusion criteria were excluded at this phase. Disagreements on inclusion of the articles were resolved by discussion among the evaluators. If an agreement could not be reached, the dispute was resolved with the help of a third investigator (SA).

Inclusion and Exclusion Criteria

We included randomized controlled trials of a single perioperative IV dexamethasone administration with an inactive (placebo or "no treatment") control group. Excluded were trials reporting nausea and vomiting after emergency medicine and nonsurgical patients. Trials in which the same subject received more than a single systemic dose of perioperative dexamethasone were also excluded to maximize clinical homogeneity. Studies involving a comparison of the combination of dexamethasone with a second antiemetic versus that of other antiemetic alone were included, with the combination group being the active group and the other antiemetic serving as control. Included studies had to report at least on early (≤6 hours) or 24-hour incidence of postoperative nausea and/or vomiting. Since we estimated the effects of a fixed dose regimen of dexamethasone, we excluded studies that used weightdependent-based dosage. We also excluded comparisons or studies that were outside the dosage range examined. Studies performed by the author Yoshitaka Fujii have been excluded because of the questioned validity of these studies' findings.5 No minimum sample size was required for inclusion in the meta-analysis.

Validity Scoring

Two authors (GSD and LJCA) independently read the included reports and assessed their methodologic validity

using a modified Jadad 5-point quality scale.⁶ The scale evaluates the study for the following: randomization, double-blind evaluation, concealment of study group to evaluator, valid randomization method, and completeness of data at follow-up. Discrepancies in rating of the trials were resolved by discussion among the evaluators. If an agreement could not be reached, the dispute was resolved with the help of a third investigator (SA). Because only randomized trials were included in the analysis, the minimum possible score of an included trial was 1, and the maximum was 5. Trials were not excluded or weighted in the analysis based on quality assessment scores.

Data Extraction

Two authors (GDO and LJCA) independently evaluated the full manuscripts of all included trials and performed data extraction using a data collection form specifically developed for this review.

Discrepancies were resolved by discussion between the 2 investigators. If an agreement could not be reached, the decision was made by a third investigator (SA). In addition, one author (MCK) cross-checked the data extraction to assure accuracy. Data extracted from trials included dexamethasone dose and time of administration, sample size, number of subjects in treatment groups, follow-up period, type of surgery, nausea and/or vomiting over 24 hours, early nausea and/or vomiting (≤ 6 hours), need for rescue antiemetics, and type of drug intervention (single regimen versus combination therapy).

Data were initially extracted from tables. For data not available in tables, attempts to contact authors were made; if the authors did not respond or did not have current contact information, the data were abstracted from available figures. Dichotomous data were extracted and converted to incidence while continuous data were recorded using mean and standard deviation. Data presented only as median and range were converted to mean and standard deviation using previously described methodology.⁷ If studies reported the proportion of patients free of nausea and/or vomiting, the actual proportion of nausea and/or vomiting was obtained by subtracting the proportion of patients not experiencing nausea and/or vomiting from one.

To perform a quantitative analysis and to examine dose dependency of the outcomes, comparisons were stratified by dose into 2 groups: 4-mg to 5-mg and 8-mg to 10-mg dose groups. The dosage ranges were derived from clinical guidelines for PONV, which suggests a 4-mg to 5-mg dose for antiemetic prophylaxis.¹ As stated in the PONV guidelines, "The corticosteroid, dexamethasone, effectively prevents nausea and vomiting. It is recommended at a prophylactic dose of 4–5 mg IV (depending on the dosage formulation in different countries) for patients at increased risk for PONV." The other dosage group represents twice the dosage range of systemic dexamethasone recommended by SAMBA guidelines for PONV. The SAMBA guidelines were developed in response to studies that have been performed to examine different dosages of dexamethasone.

Definition of Relevant Outcome Data

Our primary outcomes were 24-hour incidence of PONV (defined as nausea and/or vomiting), early (≤6 hours

postoperatively) incidence of PONV, early and 24-hour incidence of nausea, and early and 24-hour incidence of vomiting (including retching). Our secondary outcomes were early (≤ 6 hours) and 24 hours need for rescue antiemetics.

Meta-Analyses

For dichotomous data, odds ratio (OR) and 95% confidence interval (CI) are reported. The weighted mean differences with 95% CI were determined and reported for continuous data. We calculated the number needed to treat (NNT) based on the absolute risk reduction, with 95% CI as an estimate of a beneficial effect. Because of the different surgical procedures, a random-effects model was used in an attempt to generalize our findings to studies not included in our meta-analysis.8 A random-effects metaanalysis to estimate the NNT was performed by combining absolute risk differences of individual studies and also using the method of moments to estimate the variance component. Publication bias was evaluated by examining for asymmetric funnel plots using Egger regression test.⁹ A one-sided P < 0.05 was considered an indication of an asymmetric funnel plot. The heterogeneity of the included studies was considered to be present if the I2 statistic was >30%. Further analysis was planned a priori to explore relevant heterogeneity. Subgroup analysis was performed to investigate the effect of type of antiemetic intervention (single therapy versus combination therapy) and the type of anesthesia (general versus regional/local). In studies that involved more than one dose group comparison with a single control group, the control group was split according to the number of comparisons. A Q statistic was used to compare the effects between subgroups. The proportion of the total variance explained by the covariates (R^2) was calculated by dividing the random-effects pooled estimates of variance (l^2) within studies by total variance (total l^2). The value obtained was then subtracted from 1. When values were outside the range of 0% to 100%, they were set to the closest value (0% or 100%). Comparisons between the different dosage groups of dexamethasone were made using a Z test. Analysis was performed using Stata version 11 (Stata Corp, College Station, TX) and Comprehensive Meta-analysis software version 2 (Biostat, Englewood, NJ).

RESULTS

Of the 163 initially evaluated abstracts, 89 studies initially met the inclusion criteria (Fig. 1). Twenty-nine studies were subsequently excluded: 12 did not provide a direct comparison between dexamethasone and placebo,¹⁰⁻²¹ 9 did not report on the evaluated outcomes,²²⁻³⁰ 3 examined multiple doses of dexamethasone,³¹⁻³³ 3 used a weightbased dosage,³⁴⁻³⁶ and 2 used a dose range outside the predetermined dosage groups.^{37,38} Among the excluded trials, exclusion of 4 trials was performed after discussion between 2 investigators (GDO and LJCA).²⁶⁻²⁹ The characteristics of included studies are listed in Table 1. The evaluated trials included data from 6696 subjects and were published between 1994 and 2011.³⁹⁻⁹⁸ The median number of patients in the included studies receiving dexamethasone was 40. The median modified Jadad scale



Figure 1. Flow chart outlining retrieved, excluded, and evaluated randomized controlled trials. Some trials evaluated multiple doses of dexamethasone.

score was 4. The trials tested single dose dexamethasone given either preoperatively or intraoperatively for a large variety of surgical procedures. All 60 studies reported on nausea and/or vomiting. Discrepancies on data extraction were resolved with discussion between 2 investigators (GDO and LJCA) for 8 trials.^{39,40,48,52,70,81,83,93} For 2 trials, data extraction discrepancies were resolved with the help of a third investigator (SA).^{60,87}

Twenty-Four–Hour Nausea and/or Vomiting (PONV)

The effect of dexamethasone on PONV by dosing groups is presented in Figure 2. Heterogeneity was low for both dose group comparisons ($l^2 < 30\%$).

The calculated NNT values for the aggregated effect of the 4-mg to 5-mg and the 8-mg to 10-mg dose groups compared with control were 3.7 (95% CI, 3.0–4.7) and 3.8 (95% CI, 3.0–4.3), respectively. The funnel plot did not demonstrate asymmetry (P = 0.06) for the 4-mg to 5-mg group comparison but it did for the 8-mg to 10-mg dose group comparison (P = 0.003). Five studies directly compared the effect of the 8-mg to 10-mg dose group with 4-mg to 5-mg dose group on the incidence of 24-hour PONV.^{63,81,84,85,89} The combined effect showed a wide CI relative to a significant clinical benefit (OR, 0.72; 95% CI, 0.45–1.17).

Three studies provided 3 comparisons of the 4-mg to 5-mg dose used as a second antiemetic to prevent 24-hour PONV.^{54,74,93} The studies used 2 mg IV haloperidol,⁵⁴ 12.5

Table 1. Summary of Studies Included in Analysis

Authors	Year of publica- tion	Procedures	Total number treatment/ control	Treatment	of active/ control subjects involved in the combination comparison)	Type of anesthesia	Modified Jadad score (1–5)	Method of data extraction
Murphy	2011	Laparoscopic	56/59	Dexamethasone 8 mg	4 mg IV	Fentanyl/	4	Table
et al. ³⁹	2011	cholecystectomy	00,00	IV before induction (combination therapy)	ondansetron (56/59)	propofol/ sevoflurane		10.010
Mathiesen et al. ⁴⁰	2011	Tonsillectomy	43/45	Dexamethasone 8 mg IV before induction (single drug)	Not applicable	Alfentanil/ propofol/ sufentanil	5	Table
Gómez- Hernández et al. ⁴¹	2010	Mastectomy	35/35	Dexamethasone 8 mg IV before induction (single drug)	Not applicable	Fentanyl/ propofol/ nitrous oxide/ sevoflurane	4	Table/text
Sánchez- Rodríguez et al. ⁴²	2010	Laparoscopic Cholecystectomy	105/105	Dexamethasone 8 mg IV before induction (single drug)	Not applicable	Fentanyl/ propofol/ sevoflurane	3	Table/text/ Figure
Thangaswamy et al. ⁴³	2010	Laparoscopic hysterectomy	37/18	Dexamethasone 4 mg and 8 mg before induction. (single drug)	Not applicable	Fentanyl/pro- pofol/isoflu- rane/nitrous oxide	5	Table/text
Mattila et al. ⁴⁴	2010	Osteotomy	26/25	Dexamethasone 9 mg IV before induction (single drug)	Not applicable	Spinal bupiva- caine 7.5 mg	4	Table
Entezariasl et al. ⁴⁵	2010	Cataract	50/50	Dexamethasone 8 mg IV before induc- tion (single drug and combination therapy)	Metoclopramide 10 mg IV (25/25)	Fentanyl/propo- fol/nitrous oxide	4	Table/text
Alghanem et al. ⁴⁶	2010	Laparoscopic cholecystectomy	60/60	Dexamethasone 8 mg IV after induction (single drug)	Not applicable	Propofol/ tramadol	5	Table/text
Sistla et al.47	2009	Laparoscopic Cholecystectomy	36/34	Dexamethasone 8 mg IV before induction (single drug)	Not applicable	Thiopenthal/ suxametho- nium/isoflu- rane/nitrous oxide	4	Table
Wu et al.48	2009	Anorectal Surgery	30/30	Dexamethasone 5 mg IV before induction (single drug)	Not applicable	Fentanyl/propo- fol/sevoflu- rane/nitrous oxide	4	Table
Yeo et al. ⁴⁹	2009	Middle ear surgery	40/40	Dexamethasone 10 mg IV after induction (single drug)	Not applicable	Propofol/isoflu- rane/nitrous oxide	4	Table
Makhdoom and Farid ⁵⁰	2009	Middle ear surgery	40/40	Dexamethasone 10 mg IV before induc- tion (single drug and combination therapy)	Midazolam 0.075 mg/kg IV (20/20)	Fentanyl/ propofol/ isoflurane	3	Table
Fukami et al. ⁵¹	2009	Laparoscopic cholecystectomy	40/40	Dexamethasone 8 mg IV before induction (single drug)	Not applicable	Fentanyl/propofol/ sevoflurane/ nitrous oxide	3	Table/text
Mathiesen et al. ⁵²	2008	Hip Arthroplasty	42/40	Dexamethasone 8 mg IV before induction (single drug)	Not applicable	Spinal bupiva- caine 15 mg	4	Table
Gautam et al. ⁵³	2008	Laparoscopic cholecystectomy	47/48	Dexamethasone 8 mg IV before induc- tion (combination therapy)	Ondansetron 4 mg IV (47/48)	Meperidine/ thiopental/ halothane	5	Table
Chu et al. ⁵⁴	2008	Laparoscopic vaginal hysterectomy	148/147	Dexamethasone 5 mg IV after induc- tion (single drug and combination therapy)	Haloperidol 2 mg IV (74/74)	Fentanyl/ propofol/ desflurane	5	Table/text

(Continued)

Table 1. (Continued)

Authors	Year of publica- tion	Procedures	Total number treatment/ control	Treatment	combination therapy (number of active/ control subjects involved in the combination comparison)	Type of anesthesia	Modified Jadad score (1–5)	Method of data extraction
Erhan et al.55	2008	Laparoscopic cholecystectomy	20/20	Dexamethasone 8 mg IV before induction (single drug)	Not applicable	Propofol/ fentanyl/ isoflurane	4	Table
Koc et al. ⁵⁶	2007	Varicocele	40/40	Dexamethasone 8 mg IV before induction (single drug)	Not applicable	Remifentanil/ propofol/ nitrous oxide	5	Table
Moussa and Oregan ⁵⁷	2007	Laparoscopic bariat- ric surgery	30/30	Dexamethasone 8 mg IV before induc- tion (combination therapy)	Granisetron 1 mg IV (30/30)	Propofol/ sevoflurane	3	Table
Bianchin et al. ⁵⁸	2007	Laparoscopic cholecystectomy	36/37	Dexamethasone 8 mg IV before induction (single drug)	Not applicable	Fentanyl/propo- fol/sevoflu- rane/nitrous oxide	5	Table
Nesek-Adam et al. ⁵⁹	2007	Laparoscopic cholecystectomy	80/80	Dexamethasone 8 mg IV after induc- tion (single drug and combination therapy)	Metoclopramide 10 mg IV (40/40)	Fentanyl/ thiopental/ isoflurane	4	Table/text
Wu et al. ⁶⁰	2007	cesarean delivery	30/30	Dexamethasone 8 mg before induction (single drug)	Not applicable	Spinal bupiva- caine 10 mg and morphine 0.2 mg	4	Table/text
Kashmiri et al. ⁶¹	2006	Laparoscopic cholecystectomy	30/30	Dexamethasone 8 mg IV before induction (single drug)	Not applicable	Thiopental/ nalbuphine	2	Table
Chen et al.62	2006	Multiple types of surgery	350/350	Dexamethasone 10 mg IV before induction (single drug)	Not applicable	Fentanyl/ propofol/ sevoflurane	3	Table/text
Numazaki and Fujii ⁶³	2005	Dental surgery	90/30	Dexamethasone 4, 8, and 16 mg IV after induction (single drug)	Not applicable	Fentanyl/propo- fol/sevoflu- rane/nitrous oxide	5	Table
Mckean et al. ⁶⁴	2006	Tonsillectomy	24/22	Dexamethasone 10 mg IV before induc- tion (combination therapy)	Ondansetron 4 mg IV	Propofol/isoflu- rane/nitrous oxide	4	Table
Feo et al. ⁶⁵	2006	Laparoscopic cholecystectomy	49/52	Dexamethasone 8 mg IV before induction (single drug)	Not applicable	Fentanyl/ propofol/ sevoflurane	4	Table/text
Laiq et al. ⁶⁶	2005	Laparoscopic gynecologycal	50/50	Dexamethasone 10 mg IV at induction (single drug)	Not applicable	Fentanyl/ thiopental/ halothane	3	Table
Yuksek et al. ⁶⁷	2003	Laparoscopic gynecological	20/20	Dexamethasone 8 mg IV before induction (single drug)	Not applicable	Fentanyl/ propofol/ sevoflurane	4	Table
Bisgaard et al. ⁶⁸	2003	Laparoscopic cholecystectomy	40/40	Dexamethasone 8 mg IV before induction (single drug)	Not applicable	Fentanyl/ propofol	5	Table/text
Nortcliffe et al. ⁶⁹	2003	cesarean delivery	30/30	Dexamethasone 8 mg IV after induction (single drug)	Not applicable	Spinal bupiva- caine 10 mg + fentanyl 10 mcg + morphine 0.2 mg	4	Table/text
Piper et al. ⁷⁰	2003	Hysterectomy/Breast surgery	75/75	Dexamethasone 8 mg IV before induc- tion (combination therapy)	50 mg dolasetron orally (75/75)	Fentanyl/ thiopental/ desflurane	4	Table

Drug used as

Table 1. (Continued)

	Year of publica-		Total number treatment/		Drug used as combination therapy (number of active/ control subjects involved in the combination	Type of	Modified Jadad score	Method of data
Authors	tion	Procedures	control	Treatment	comparison)	anesthesia	(1–5)	extraction
Biswas et al. ⁷¹	2003	Laparoscopic cholecystectomy	60/60	Dexamethasone 8 mg IV before induc- tion (combination therapy)	Granisetron 40 mcg/kg IV (60/60)	Meperidine/ thiopental/ halothane/ nitrous oxide	5	Table
Elhakim et al. ⁷²	2002	Laparoscopic cholecystectomy	120/30	Dexamethasone 2, 4, 8, and 16 mg IV before induc- tion (combination therapy)	Ondasetron 4 mg IV (60/30)	Fentanyl/pro- pofol/isoflu- rane/nitrous oxide	4	Tables
Wang et al. ⁷³	2002	Middle ear surgery	40/40	Dexamethasone 5 mg IV after induction (single drug)	Not applicable	Fentanyl/ thiopental/ sevoflurane/ desflurane	3	Table
Coloma et al. ⁷⁴	2002	Laparoscopic cholecystectomy	70/70	Dexamethasone 4 mg IV after induc- tion (combination therapy)	Dolasetron 12.5 mg IV (70/70)	Fentanyl/propo- fol/sevoflu- rane/nitrous oxide	3	Table
Goksu et al. ⁷⁵	2002	Otologic Surgery	20/20	Dexamethasone 8 mg IV after induc- tion (combination therapy)	Granisetron 3 mg IV (20/20)	Thiopental// isoflurane	4	Table
Wang et al. ⁷⁶	2002	Laparoscopic Cholecystectomy	38/39	Dexamethasone 5 mg IV after induction (single drug)	Not applicable	Fentanyl/ propofol/ isoflurane	5	Table
Tzeng et al.77	2002	Abdominal hysterectomy	38/38	Dexamethasone 5 mg IV after induction (single drug)	Not applicable	Epidural lidocaine	3	Table
Wang et al. ⁷⁸	2002	Total Hysterectomy	39/37	Dexamethasone 5 mg IV after induction (single drug)	Not applicable	Epidural lidocaine	5	Table
Tzeng et al. ⁷⁹	2000	cesarean delivery	38/37	Dexamethasone 8 mg IV after induction (single drug)	Not applicable	Epidural lidocaine	3	Table
Thomas and Jones ⁸⁰	2001	Laparoscopic gynecologic	58/59	Dexamethasone 8 mg IV after induc- tion (combination therapy)	Ondansetron 4 mg IV (58/59)	Fentanyl/propo- fol/sevoflu- rane/nitrous oxide	3	Table
Lee et al. ⁸¹	2001	Thyroidectomy	88/44	Dexamethasone 5 mg and 8 mg IV before induction (single drug)	Not applicable	Fentanyl/thio- pental/desflu- rane/nitrous oxide	3	Table
Huang et al. ⁸²	2001	Laparoscopic tubal ligation	39/38	Dexamethasone 5 mg IV after induction (single drug)	Not applicable	Fentanyl/ propofol/ isoflurane	3	Table
Liu et al. ⁸³	2001	Middle ear surgery	40/40	Dexamethasone 10 mg IV after induction (single drug)	Not applicable	Fentanyl/ propofol/ isoflurane	4	Table
Ho et al. ⁸⁴	2001	Total abdominal hysterectomy	129/43	Dexamethasone 2.5, 5, and 10 mg IV after induction (single drug)	Not applicable	Epidural lidocaine	4	Table/text
Wang et al. ⁸⁵	2001	Cesarean delivery	131/44	Dexamethasone 2.5, 5, and 10 mg IV after induction (single drug)	Not applicable	Epidural lidocaine	4	Table/text
Tan et al. ⁸⁶	2001	Inguinal hernia repair	30/30	Dexamethasone 10 mg IV before induction (single drug)	Not applicable	Spinal tetracaine 15 mg + neostigmine 100 µg	4	Table

Anesthesia & Analgesia

(Continued)

Table 1. (Continued)

Authors	Year of publica- tion	Procedures	Total number treatment/ control	Treatment	combination therapy (number of active/ control subjects involved in the combination comparison)	Type of anesthesia	Modified Jadad score (1–5)	Method of data extraction
Coloma et al. ⁸⁷	2001	Anorectal surgery	40/40	Dexamethasone 4 mg IV before induction (single drug)	Not applicable	Propofol/ fentanyl	2	Table/text
Tzeng et al. ⁸⁸	2000	Dilation and Curettage	75/76	Dexamethasone 8 mg IV before induc- tion (single drug and combination therapy)	Droperidol 1.25 mg IV (37/36)	Propofol/ fentanyl	3	Table
Wang et al. ⁸⁹	2000	Thyroidectomy	173/44	Dexamethasone 1.25, 2.5, 5, and 10 mg IV after induction (single drug)	Not applicable	Fentanyl/ propofol/ isoflurane	4	Table
Wang et al.90	2000	Abdominal Hysterectomy	80/40	Dexamethasone 10 mg IV before and after induction (single drug)	Not applicable	Fentanyl/ propofol/ isoflurane	3	Table
Wang et al.91	2000	Laparoscopic tubal ligation	41/40	Dexamethasone 10 mg IV, no time specifica- tion (single drug)	Not applicable	Fentanyl/ thiopental/ isoflurane	4	Table
Wang et al. ⁹²	1999	Laparoscopic cholecystectomy	40/40	Dexamethasone 8 mg IV before induction (single drug)	Not applicable	Fentanyl/ propofol/ isoflurane	5	Table
Janknegt et al. ⁹³	1999	Multiple surgery types	130/130	Dexamethasone 5 mg IV before induc- tion (combination therapy)	Granisetron 1 mg IV (130/130)	Not standardized	2	Table
Wang et al. ⁹⁴	1999	Thyroidectomy	38/38	Dexamethasone 10 mg IV before induction (single drug)	Not applicable	Fentanyl/ propofol/ isoflurane	4	Table
Wang et al.95	1999	Abdominal hysterectomy	36/36	Dexamethasone 8 mg IV after induction (single drug)	Not applicable	Epidural lidocaine	3	Table/text
Rajeeva et al.96	1999	Diagnostic Iaparoscopic	25/26	Dexamethasone 8 mg IV after induc- tion (combination therapy)	Ondansetron 4 mg IV (25/26)	Thiopental/ nitrous oxide	3	Table/text
López- Olaondo et al. ⁹⁷	1996	Major gynecological surgery	50/50	Dexamethasone 8 mg IV before induc- tion (single drug and combination therapy)	Ondansetron 4 mg IV (25/25)	Fentanyl/thio- pental/isoflu- rane/nitrous oxide	3	Table
Mckenzie et al. ⁹⁸	1994	Major gynecological surgery	91/89	Dexamethasone 8 mg IV after induction (combination therapy)	Ondansetron 4 mg IV (91/89)	Not standardized	3	Text

Drug used as

mg IV dolasetron,⁷⁴ and 1 mg IV granisentron⁹³ as the first antiemetic. The 4-mg to 5-mg dose dexamethasone group showed a benefit compared with the control group when used with a second antiemetic (OR, 0.50; 95% CI, 0.35–0.72; NNT, 6.6; 95% CI, 4.3–12.8). Seven studies provided 7 comparisons of 8-mg to 10-mg dose used with a second antiemetic to prevent 24-hour PONV.^{50,53,57,59,70,71,88} The studies used 0.075 mg/kg IV midazolam,⁵⁰ 4 mg IV ondasentron,⁵³ 1 mg IV granisetron,⁵⁷ 10 mg IV metoclopramide,⁵⁹ 50 mg per os dolasetron, ⁷⁰ 40 µg/kg granisetron,⁷¹ and 1.25 mg IV droperidol⁸⁸ as the first antiemetic. The 8-mg to 10-mg dexamethasone dose group also showed a benefit compared

with control when used with a second antiemetic (OR, 0.35; 95% CI, 0.22–0.53; NNT, 6.2; 95% CI, 4.5–10).

The effect of dexamethasone on 24-hour incidence of PONV was not significantly different for studies performed under general anesthesia (OR, 0.29; 95% CI, 0.24–0.35) compared with studies performed under regional/local anesthesia (OR, 0.26; 95% CI, 0.17–0.38; P = 0.10).

Early (0-6 Hours) Nausea and/or Vomiting

The effect of dexamethasone on early PONV by dosing groups is shown in Figure 3. The calculated NNT values for the aggregated effects of the 4-mg to 5-mg and the 8-mg

Group by	Study name	Comparisor	Outcome	Statistic	s for e	ach stud	y	Events /	Total		Odds ratio and 95% Cl
Comparison			Odds	Lower	Upper						
			ratio	limit	limit	Z-Value p	-Value D	examethason	e Control		
4-5 mg	Chu ref 54	4-5 mg	PONV 24 hr 0.323	0.166	0.630	-3.314	0.001	28/74	49 / 75	- I	
4-5 mg	Chu 2 ref 54	4-5 mg	PONV 24 hr 0.389	0.183	0.825	-2.460	0.014	14/74	27 / 72		
4-5 mg	Numazaki ref 63	4-5 mg	PONV 24 hr 0.868	0.243	3.099	-0.217	0.828	11/30	6/15		
4-5 mg	Wang ref 73	4-5 mg	PONV 24 hr 0.193	0.073	0.510	-3.316	0.001	10/39	25 / 39		
4-5 mg	Coloma ref 74	4-5 mg	PONV 24 hr 0.623	0.316	1.227	-1.369	0.171	25/70	33 / 70		
4-5 mg	Wang ref 76	4-5 mg	PONV 24 hr 0.200	0.075	0.530	-3.237	0.001	10/38	25 / 39		+
4-5 mg	Tzeng ref 77	4-5 mg	PONV 24 hr 0.289	0.110	0.758	-2.522	0.012	10/38	21/38		
4-5 mg	Wang ref 78	4-5 mg	PONV 24 hr 0.176	0.064	0.487	-3.348	0.001	8/39	22/37		
4-5 mg	Lee ref 81	4-5 mg	PONV 24 hr 0.087	0.022	0.340	-3.512	0.000	16 / 45	19/22		
4-5 mg	Huang ref 82	4-5 mg	PONV 24 hr 0.229	0.088	0.598	-3.009	0.003	11/39	24 / 38		
4-5 mg	Shung-Tai ref 84	4-5 mg	PONV 24 hr 0.227	0.074	0.694	-2.600	0.009	9/42	12/22		
4-5 mg	Wang ref 85	4-5 mg	PONV 24 hr 0.222	0.072	0.690	-2.600	0.009	8/44	11/22		
4-5 mg	Wang 89	4-5 mg	PONV 24 hr 0.220	0.056	0.861	-2.175	0.030	4/43	7/22		
4-5 mg	Janknegt ref 93	4-5 mg	PONV 24 hr 0.513	0.312	0.845	-2.620	0.009	45 / 130	66 / 130		
4-5 mg			0.312	0.235	0.415	-8.032	0.000	209 / 745	347 / 641		
8-10 mg	Alghanem ref 46	8-10 mg	PONV 24 hr 0.857	0.397	1.851	-0.392	0.695	18 / 60	20 / 60		
8-10 mg	Yeo ref 49	8-10 mg	PONV 24 hr 0.290	0.116	0.727	-2.641	0.008	14 / 40	26 / 40		
8-10 mg	Makhdoom ref 50	8-10 mg	PONV 24 hr 0.231	0.061	0.869	-2.167	0.030	7/20	14/20		
8-10 mg	Makhdoom 2 ref 50	8-10 mg	PONV 24 hr 0.529	0.108	2.598	-0.784	0.433	3/20	5/20		
8-10 mg	Gautam ref 53	8-10 mg	PONV 24 hr 0.238	0.079	0.718	-2.547	0.011	5/47	16 / 48		
8-10 mg	Erhan ref 55	8-10 mg	PONV 24 hr 0.111	0.027	0.465	-3.009	0.003	5/20	15/20		
8-10 mg	Koc ref 56	8-10 mg	PONV 24 hr 0.179	0.046	0.704	-2.463	0.014	7/20	15 / 20		
8-10 mg	Koc 2 ref 56	8-10 mg	PONV 24 hr 0.079	0.009	0.713	-2.261	0.024	1/20	8/20	÷	
8-10 mg	Moussa ref 57	8-10 mg	PONV 24 hr 0.583	0.178	1.913	-0.890	0.374	6/30	9/30		
8-10 mg	Biachin ref 58	8-10 mg	PONV 24 hr 0.208	0.077	0.563	-3.094	0.002	10/36	24/37		
8-10 mg	Nasek-Adam ref 59	8-10 mg	PONV 24 hr 0.194	0.073	0.513	-3.301	0.001	9/40	24 / 40		
8-10 mg	Nasek-Adam 2 ref	5 9 -10 mg	PONV 24 hr 0.175	0.057	0.538	-3.040	0.002	5/40	18 / 40		
8-10 mg	Wu ref 60	8-10 mg	PONV 24 hr 0.765	0.277	2.114	-0.517	0.605	13/30	15/30		
8-10 mg	Mckean ref 64	8-10 mg	PONV 24 hr 0.121	0.032	0.458	-3.111	0.002	7/24	17 / 22		
8-10 mg	Feo ref 65	8-10 mg	PONV 24 hr 0.194	0.074	0.512	-3.315	0.001	7/49	24 / 52		
8-10 mg	Yusek ref 67	8-10 mg	PONV 24 hr 0.216	0.048	0.977	-1.990	0.047	11/20	17 / 20		
8-10 mg	Bisgaard ref 68	8-10 mg	PONV 24 hr 0.436	0.176	1.079	-1.795	0.073	13 / 40	21 / 40		
8-10 mg	Piper ref 70	8-10 mg	PONV 24 hr 0.351	0.148	0.828	-2.389	0.017	9/75	21/75		
8-10 mg	Biswas ref 71	8-10 mg	PONV 24 hr 0.234	0.062	0.889	-2.134	0.033	3 / 60	11/60		
8-10 mg	Tzeng ref 79	8-10 mg	PONV 24 hr 0.214	0.075	0.607	-2.897	0.004	7/38	19/37		
8-10 mg	Liu ref 83	8-10 mg	PONV 24 hr 0.135	0.049	0.370	-3.887	0.000	8/40	26 / 40		
8-10 mg	Tzeng ref 88	8-10 mg	PONV 24 hr 0.732	0.300	1.785	-0.685	0.493	17 / 38	21 / 40		
8-10 mg	Tzeng 2 ref 88	8-10 mg	PONV 24 hr 0.700	0.229	2.137	-0.626	0.531	7/37	9/36		
8-10 mg	Wang ref 91	8-10 mg	PONV 24 hr 0.197	0.076	0.507	-3.363	0.001	14 / 41	29 / 40		
8-10 mg	Wang ref 92	8-10 mg	PONV 24 hr 0.169	0.063	0.457	-3.506	0.000	9/40	24/38		+
8-10 mg	Wang ref 94	8-10 mg	PONV 24 hr 0.161	0.059	0.441	-3.560	0.000	13 / 38	29/38		
8-10 mg	Wang ref 95	8-10 mg	PONV 24 hr 0.150	0.050	0.447	-3.405	0.001	6/38	20 / 36		
8-10 mg			0.274	0.215	0.350	-10.346	0.000	234 / 1001	497 / 999		
Overall			0.290	0.241	0.349	-13.081	0.000	443 / 1746	844 / 1640		
										0.01	0.1 1 10 100
											Active Control

Meta Analysis

Figure 2. Pooled data evaluating the effect of systemic dexamethasone on the 24-hour incidence of postoperative nausea and vomiting (PONV) compared with control. Data were evaluated by calculating the odds ratio. The point estimate for the overall effect was 0.29 (95% confidence interval [CI], 0.24–0.34). Thirty studies examined dexamethasone used as a single prophylactic drug. The odds ratio for individual studies is represented by a square on forest plot with 95% CI of the difference shown as a solid line. Larger-sized square and thicker 95% CI line denote larger sample size. The diamonds represent the pooled estimate and uncertainty for the effects of the 4-mg to 5-mg dexamethasone dose group, the 8-mg to 10-mg dexamethasone dose group, and the overall effect.

to 10-mg dose groups were 10 (95% CI, 5.5–76.9) and 5.5 (95% CI, 4.0–9.0), respectively. Heterogeneity was low for the 4-mg to 5-mg dose group ($I^2 = 0$) and mild for the 8-mg to 10-mg dose group ($I^2 = 33\%$). Heterogeneity could not be explained by studies evaluating dexamethasone with a second antiemetic. An examination of the funnel plot did not reveal asymmetry for the 4-mg to 5-mg dose group (P = 0.16) but it did for the 8-mg to 10-mg dose group (P = 0.01), suggesting the possibility of publication bias.

Eight studies provided 8 comparisons of 8-mg to 10-mg doses of dexamethasone to prevent early PONV when used with a second antiemetic.^{53,57,70,71,72,75,80,88} The studies used 4 mg IV ondansetron,^{53,72,80} 1 mg IV granisetron,⁵⁷ 50 mg per os dolasetron,⁷⁰ 40 µg/kg granisetron,⁷¹ 3 mg IV granisetron,⁷⁵ and 1.25 mg IV droperidol⁸⁸ as the other antiemetic. Subgroup analysis showed a statistically significant reduction in the incidence of early PONV in the 8-mg to 10-mg dexamethasone dosage with a second antiemetic group (NNT, 12.5; 95% CI, 8.3–33.3). Two studies examined the effect of the 4-mg to 5-mg doses used with a second antiemetic, but neither showed a significant

benefit compared with control. 54,72 The studies used 2 mg IV haloperidol 54 and 4 mg IV ondansetron 72 as the first antiemetic.

Twenty-Four–Hour Incidence of Nausea

The overall effect of dexamethasone (as a single drug or as part of a combined regimen) on the 24-hour incidence of nausea compared with control is presented in Figure 4. Heterogeneity was low ($I^2 = 0$) for both dose group comparisons.

The calculated NNT values for the combined effect of the 4-mg to 5-mg and the 8-mg to 10-mg dose groups were 7.1 (95% CI, 5.3–11.1) and 7.5 (95% CI, 6.0–10.2), respectively. The funnel plot did not show asymmetry for the 4-mg to 5-mg dose (P = 0.08) but it did for the 8-mg to 10-mg dose group (P = 0.003). Five studies directly compared the 8-mg to 10-mg with the 4-mg to 5-mg dose groups on the incidence of the 24-hour nausea.^{63,81,84,85,89} The combined effect showed a wide CI relative to a significant clinical benefit (OR, 0.86; 95% CI, 0.47–1.55).

Meta	Ana	lvsis
motu	Ana	1,9010

Group by	Study name	Comparison	Outcome		Statis	tics for ea	ch study	-	Events / 1	otal	Odds ratio and 95% CI
companyon				Odds ratio	Lower	Upper limit	Z-Value	p-Value	Dexamethasone	Control	
4-5 mg	Chu ref 54	4-5 mg	Early PONV	0.647	0.218	1.919	-0.785	0.433	6/74	9/75	
4-5 mg	Chu 2 ref 54	4-5 mg	Early PONV	0.766	0.197	2.974	-0.386	0.700	4/74	5/72	
4-5 mg	Elhakim ref 72	4-5 mg	Early PONV	0.444	0.078	2.529	-0.914	0.381	3/30	3/15	
4-5 mg	Tzeng ref 77	4-5 mg	Early PONV	0.457	0.105	1.981	-1.048	0.295	3/38	6/38	
4-5 mg	Lee ref 81	4-5 mg	Early PONV	0.232	0.079	0.685	-2.646	0.008	13 / 45	14/22	│ ┿╋━─│ │ │
4-5 mg	Huang ref 82	4-5 mg	Early PONV	0.218	0.082	0.584	-3.030	0.002	9/39	22/38	
4-5 mg				0.378	0.230	0.620	-3.850	0.000	38 / 300	59 / 260	
8-10 mg	Gomez-hernandez ref 41	8-10 mg	Early PONV	0.267	0.098	0.723	-2.597	0.009	10 / 35	21/35	
8-10 mg	Thangaswamy ref 43	8-10 mg	Early PONV	0.020	0.001	0.404	-2.550	0.011	5/19	9/9	
8-10 mg	Gautam ref 53	8-10 mg	Early PONV	0.326	0.033	3.253	-0.955	0.340	1 / 47	3 / 48	
8-10 mg	Moussa ref 57	8-10 mg	Early PONV	0.615	0.155	2.450	-0.689	0.491	4/30	6/30	
8-10 mg	Nasek-Adam ref 59	8-10 mg	Early PONV	0.265	0.090	0.775	-2.428	0.015	6 / 40	16 / 40	
8-10 mg	Kashmiri ref 61	8-10 mg	Early PONV	0.222	0.054	0.914	-2.085	0.037	3/30	10 / 30	
8-10 mg	Chen ref 62	8-10 mg	Early PONV	0.662	0.423	1.038	-1.798	0.072	37 / 350	53 / 350	
8-10 mg	Laig ref 66	8-10 mg	Early PONV	0.299	0.129	0.695	-2.809	0.005	13 / 50	27 / 50	
8-10 mg	Bisgaard ref 68	8-10 mg	Early PONV	0.379	0.150	0.962	-2.042	0.041	11 / 40	20 / 40	
8-10 mg	Piper ref 70	8-10 mg	Early PONV	0.503	0.207	1.223	-1.518	0.130	9/75	16 / 75	
8-10 mg	Biswas ref 71	8-10 mg	Early PONV	0.263	0.069	1.010	-1.945	0.052	3/60	10 / 60	
8-10 mg	Goksu ref 75	8-10 mg	Early PONV	1.000	0.259	3.867	0.000	1.000	6/20	6/20	
8-10 mg	Thomas ref 80	8-10 mg	Early PONV	0.334	0.111	1.007	-1.947	0.052	5/58	13 / 59	
8-10 mg	Tzeng ref 88	8-10 mg	Early PONV	0.875	0.351	2.182	-0.286	0.775	14/38	16 / 40	
8-10 mg	Tzeng 2 ref 88	8-10 mg	Early PONV	0.969	0.255	3.679	-0.047	0.963	5/37	5/38	
8-10 mg	Wang ref 90	8-10 mg	Early PONV	0.818	0.279	2.398	-0.388	0.715	18 / 40	10 / 20	
8-10 mg	Wang 2 ref 90	8-10 mg	Early PONV	0.176	0.051	0.606	-2.758	0.006	6 / 40	10 / 20	
8-10 mg	Wang ref 91	8-10 mg	Early PONV	0.220	0.086	0.584	-3.151	0.002	11 / 41	25 / 40	
8-10 mg				0.420	0.315	0.559	-5.914	0.000	167 / 1050	276 / 1002	
Overall				0.409	0.319	0.524	-7.048	0.000	205 / 1350	335 / 1262	
											0.01 0.1 1 10 100
											Active Control

Figure 3. Pooled data evaluating the effect of systemic dexamethasone on the early (\leq 6 hours) incidence of postoperative nausea and vomiting (PONV) compared with control. Data were evaluated by calculating the odds ratio. The point estimate for the overall effect was 0.40 (95% confidence interval [CI], 0.31–0.52). Fourteen studies examined dexamethasone used as a single prophylactic drug. The odds ratio for individual studies is represented by a square on the forest plot with 95% CI of the difference shown as a solid line. Larger-sized square and thicker 95% CI line denote larger sample size. The diamonds represent the pooled estimate and uncertainty for the effects of the 4-mg to 5-mg dexamethasone dose group, the 8-mg to 10-mg dexamethasone dose group, and the overall effect.

Meta Analysis

Group by	Study name	Comparison	Outcome		Statist	ics for ea	ch study		Events / 1	otal	Odds ratio and 95% Cl
Comparison				Odds ratio	Lower	Upper limit	Z-Value	p-Value	Dexamethasone	Control	
4-5 mg	Chu ref 54	4-5 mg	Nausea 24 hr	0.813	0.380	1.738	-0.534	0.593	16/74	19/75	
4-5 mg	Chu 2 ref 54	4-5 mg	Nausea 24 hr	0.329	0.111	0.977	-2.003	0.045	5/74	13/72	
4-5 mg	Numazaki ref 63	4-5 mg	Nausea 24 hr	0.800	0.163	3.916	-0.275	0.783	5/30	3/15	
4-5 mg	Wang ref 73	4-5 mg	Nausea 24 hr	0.291	0.098	0.859	-2.235	0.025	6/39	15/39	
4-5 mg	Wang ref 76	4-5 mg	Nausea 24 hr	0.335	0.113	0.996	-1.967	0.049	6/38	14/39	
4-5 mg	Tzeng ref 77	4-5 mg	Nausea 24 hr	0.408	0.134	1.231	-1.593	0.111	6/38	12/38	
4-5 mg	Wang ref 78	4-5 mg	Nausea 24 hr	0.308	0.098	0.981	-1.992	0.048	5/39	12/37	
4-5 mg	Huang ref 82	4-5 mg	Nausea 24 hr	0.498	0.178	1.385	-1.338	0.181	8/39	13 / 38	
4-5 mg	Shung-Tai ref 84	4-5 mg	Nausea 24 hr	0.290	0.079	1.057	-1.876	0.061	5/42	7/22	
4-5 mg	Wang ref 85	4-5 mg	Nausea 24 hr	0.342	0.091	1.282	-1.591	0.111	5/44	6/22	
4-5 mg	Wang 89	4-5 mg	Nausea 24 hr	0.282	0.077	1.028	-1.918	0.055	5/43	7 / 22	
4-5 mg	Janknegt ref 93	4-5 mg	Nausea 24 hr	0.561	0.340	0.926	-2.263	0.024	44 / 130	62 / 130	
4-5 mg				0.460	0.348	0.607	-5.477	0.000	116 / 630	183 / 549	
8-10 mg	Sistla ref 47	8-10 mg	Nausea 24 hr	0.350	0.133	0.923	-2.122	0.034	13/38	21/34	
8-10 mg	Entezariasl ref 45	8-10 mg	Nausea 24 hr	0.231	0.066	0.810	-2.289	0.022	5/25	13 / 25	
8-10 mg	EntezariasI 2 ref 45	8-10 mg	Nausea 24 hr	0.348	0.061	1.993	-1.186	0.238	2/25	5/25	
8-10 mg	Alghanem ref 46	8-10 mg	Nausea 24 hr	1.383	0.554	3.455	0.694	0.488	13/60	10 / 60	
8-10 mg	Yeo ref 49	8-10 mg	Nausea 24 hr	0.328	0.111	0.969	-2.017	0.044	6 / 40	14 / 40	
8-10 mg	Makhdoom ref 50	8-10 mg	Nausea 24 hr	0.375	0.091	1.543	-1.359	0.174	4 / 20	8 / 20	
8-10 mg	Makhdoom 2 ref 50	8-10 mg	Nausea 24 hr	0.630	0.093	4.244	-0.475	0.635	2/20	3 / 20	
8-10 mg	Fukami ref 51	8-10 mg	Nausea 24 hr	0.318	0.113	0.893	-2.175	0.030	7 / 40	16 / 40	
8-10 mg	Gautam ref 53	8-10 mg	Nausea 24 hr	0.229	0.059	0.884	-2.139	0.032	3/47	11 / 48	
8-10 mg	Erhan ref 55	8-10 mg	Nausea 24 hr	0.079	0.009	0.713	-2.261	0.024	1/20	8 / 20	
8-10 mg	Kooref 56	8-10 mg	Nausea 24 hr	0.317	0.012	8.260	-0.691	0.490	0/20	1/20	
8-10 mg	Koc 2 ref 56	8-10 mg	Nausea 24 hr	0.317	0.012	8.260	-0.691	0.490	0 / 20	1/20	
8-10 mg	Moussa ref 57	8-10 mg	Nausea 24 hr	1.000	0.185	5.403	0.000	1.000	3/30	3/30	
8-10 mg	Biachin ref 58	8-10 mg	Nausea 24 hr	0.417	0.137	1.270	-1.540	0.124	6/36	12/37	
8-10 mg	Feo ref 65	8-10 mg	Nausea 24 hr	0.241	0.073	0.795	-2.338	0.019	4 / 49	14/52	
8-10 mg	Yusek ref 67	8-10 mg	Nausea 24 hr	1.000	0.239	4.184	0.000	1.000	5/20	5/20	
8-10 mg	Bisgaard ref 68	8-10 mg	Nausea 24 hr	0.474	0.189	1.186	-1.598	0.111	12 / 40	19 / 40	
8-10 mg	Nortcliffe ref 69	8-10 mg	Nausea 24 hr	0.750	0.262	2.151	-0.535	0.592	18 / 30	20 / 30	
8-10 mg	Piper ref 70	8-10 mg	Nausea 24 hr	0.594	0.240	1.471	-1.125	0.261	9/75	14/75	
8-10 mg	Lee ref 81	8-10 mg	Nausea 24 hr	0.284	0.083	0.965	-2.017	0.044	6/43	8/22	
8-10 mg	Tzeng ref 79	8-10 mg	Nausea 24 hr	0.278	0.079	0.974	-2.002	0.045	4/38	11/37	
8-10 mg	Liu ref 83	8-10 mg	Nausea 24 hr	0.238	0.077	0.741	-2.479	0.013	5/40	15 / 40	
8-10 mg	Ping-Heng ref 86	8-10 mg	Nausea 24 hr	0.722	0.147	3.545	-0.401	0.688	3/30	4/30	
8-10 mg	Tzeng ref 88	8-10 mg	Nausea 24 hr	0.951	0.359	2.518	-0.102	0.919	11/38	12 / 40	
8-10 mg	Tzeng 2 ref 88	8-10 mg	Nausea 24 hr	0.752	0.185	3.057	-0.399	0.690	4/37	5/38	
8-10 mg	Wang ref 91	8-10 mg	Nausea 24 hr	0.538	0.206	1.401	-1.270	0.204	10/41	15/40	
8-10 mg	Wang ref 92	8-10 mg	Nausea 24 hr	0.351	0.109	1.130	-1.755	0.079	5/40	11/38	
8-10 mg	wang ref 94	8-10 mg	Nausea 24 hr	0.554	0.188	1.630	-1.072	0.284	7/38	11/38	
6-10 mg	wang ret 35	6-10 mg	rvausea 24 hr	0.267	0.078	0.938	-2.059	0.039	4/38	11/30	
e-ru mg	Lopez-Olaondo ret 97	6-10 mg	wausea 24 hr	0.211	0.002	0.711	-2.008	0.012	10/25	19/20	
e-iving	Lopez-Olaondo 2 réf 97	e-10 mg	wausea 24 hr	0.148	0.035	0.023	-2.005	0.009	3/20	12/20	
s-10 mg				0.432	0.347	0.537	-7.521	0.000	185/1086	33271063	
Overall				0.442	0.372	0.525	-9.298	0.000	301 / 1716	515/1012	
											0.01 0.1 1 10 100
											and a started
											Active Control

Meta Analysis

Figure 4. Pooled data evaluating the effect of systemic dexamethasone on the 24-hour incidence of nausea compared with control. Data were evaluated by calculating the odds ratio. The point estimate for the overall effect was 0.42 (95% confidence interval [CI], 0.37–0.52). Thirty-three studies examined dexamethasone used as a single prophylactic drug. The odds ratio for individual studies is represented by a square on the forest plot with 95% CI of the difference shown as a solid line. Larger-sized square and thicker 95% CI line denote larger sample size. The diamonds represent the pooled estimate and uncertainty for the effects of the 4-mg to 5-mg dexamethasone dose group, the 8-mg to 10-mg dexamethasone dose group, and the overall effect.

Group by	Study name	Comparison	Outcome		Statist	ics for ea	ich study	-	Events / 1	fotal	Odds ratio and 95% CI
Comparison				Odds	Lower	Upper					
				ratio	limit	limit	Z-Value	p-Value	Dexamethasone	Control	
4-5 mg	Wu ref 48	4-5 mg	Early Nausea	0.138	0.016	1.226	-1.777	0.076	1/30	6/30	
4-5 mg	Chu ref 54	4-5 mg	Early Nausea	1.014	0.244	4.216	0.020	0.984	4/74	4 / 75	
4-5 mg	Chu 2 ref 54	4-5 mg	Early Nausea	0.639	0.104	3.941	-0.483	0.629	2/74	3/72	
4-5 mg	Elhakim ref 72	4-5 mg	Early Nausea	1.558	0.148	16.367	0.368	0.713	3 / 30	1/15	
4-5 mg	Coloma ref 74	4-5 mg	Early Nausea	0.588	0.299	1.158	-1.536	0.125	25 / 70	34 / 70	
4-5 mg	Tzeng ref 77	4-5 mg	Early Nausea	0.472	0.081	2.747	-0.835	0.404	2/38	4/38	
4-5 mg	Lee ref \$1	4-5 mg	Early Nausea	0.395	0.118	1.319	-1.510	0.131	7/45	7/22	
4-5 mg	Huang ref 82	4-5 mg	Early Nausea	0.394	0.130	1.191	-1.650	0.099	6/39	12 / 38	
4-5 mg	Coloma ref 87	4-5 mg	Early Nausea	0.325	0.013	8.222	-0.682	0.495	0 / 40	1 / 40	
4-5 mg				0.529	0.342	0.817	-2.872	0.004	50 / 440	72 / 400	
8-10 mg	Murphy ref 39	8-10 mg	Early Nausea	0.240	0.093	0.622	-2.937	0.003	7/56	22 / 59	
8-10 mg	Sanchez-Rodriguez ref 42	8-10 mg	Early Nausea	0.504	0.282	0.901	-2.311	0.021	28 / 105	44 / 105	
8-10 mg	Sistla ref 47	8-10 mg	Early Nausea	0.446	0.171	1.165	-1.648	0.099	13 / 36	19/34	
8-10 mg	Entezariasl ref 45	8-10 mg	Early Nausea	0.242	0.064	0.916	-2.089	0.037	4 / 25	11/25	
8-10 mg	Entezariasl 2 ref 45	8-10 mg	Early Nausea	0.348	0.061	1.993	-1.188	0.238	2/25	5/25	
8-10 mg	Alghanem ref 46	8-10 mg	Early Nausea	0.841	0.265	2.669	-0.293	0.769	6/60	7/60	
8-10 mg	Gautam ref 53	8-10 mg	Early Nausea	0.500	0.044	5.708	-0.558	0.577	1 / 47	2/48	
8-10 mg	Erhan ref 55	8-10 mg	Early Nausea	0.079	0.009	0.713	-2.261	0.024	1 / 20	8 / 20	
8-10 mg	Moussa ref 57	8-10 mg	Early Nausea	1.000	0.131	7.605	0.000	1.000	2/30	2/30	
8-10 mg	Nasek-Adam ref 59	8-10 mg	Early Nausea	0.181	0.038	0.901	-2.087	0.037	2/40	9 / 40	
8-10 mg	Nasek-Adam 2 ref 59	8-10 mg	Early Nausea	0.248	0.048	1.278	-1.667	0.096	2 / 40	7 / 40	
8-10 mg	Kashmiri ref 61	8-10 mg	Early Nausea	0.196	0.038	1.020	-1.937	0.053	2/30	8/30	
8-10 mg	Chen ref 62	8-10 mg	Early Nausea	1.378	0.679	2.793	0.888	0.374	19 / 350	14 / 350	
8-10 mg	Laig ref 66	8-10 mg	Early Nausea	0.583	0.233	1.463	-1.149	0.251	10 / 50	15 / 50	
8-10 mg	Bisgaard ref 68	8-10 mg	Early Nausea	0.368	0.143	0.950	-2.066	0.039	10 / 40	19 / 40	
8-10 mg	Biswas ref 71	8-10 mg	Early Nausea	0.310	0.060	1.604	-1.398	0.163	2/60	6/60	
8-10 mg	Goksu ref 75	8-10 mg	Early Nausea	0.706	0.138	3.658	-0.415	0.678	3 / 20	4 / 20	
8-10 mg	Thomas ref 80	8-10 mg	Early Nausea	0.334	0.111	1.007	-1.947	0.052	5/58	13 / 59	
8-10 mg	Tzeng ref 88	8-10 mg	Early Nausea	0.931	0.331	2.621	-0.135	0.892	9/38	10 / 40	
8-10 mg	Tzeng 2 ref 88	8-10 mg	Early Nausea	0.971	0.183	5.158	-0.035	0.972	3/37	3/38	
8-10 mg	Wang ref 90	8-10 mg	Early Nausea	0.778	0.238	2.568	-0.412	0.680	10 / 40	6/20	
8-10 mg	Wang 2 ref 90	8-10 mg	Early Nausea	0.259	0.063	1.060	-1.879	0.060	4 / 40	6/20	
8-10 mg	Wang ref 91	8-10 mg	Early Nausea	0.450	0.164	1.235	-1.550	0.121	8 / 41	14 / 40	
8-10 mg	Rajeeva ref 96	8-10 mg	Early Nausea	0.308	0.012	7.927	-0.710	0.477	24 / 25	26/26	
8-10 mg	Lopez-Olaondo ref 97	8-10 mg	Early Nausea	0.375	0.108	1.329	-1.519	0.129	5/25	10 / 25	
8-10 mg	Lopez-Olaondo 2 ref 97	8-10 mg	Early Nausea	0.306	0.030	3.159	-0.995	0.320	1/25	3/25	
8-10 mg				0.490	0.389	0.617	-6.065	0.000	183 / 1363	293 / 1327	
Overall				0.498	0.408	0.611	-8.704	0.000	233 / 1803	385 / 1727	
											0.01 0.1 1 10 100
											Activo Control
											Active Control

Meta Analysis

Figure 5. Pooled data evaluating the effect of systemic dexamethasone on the early (≤ 6 hours) incidence of nausea compared with control. Data were evaluated by calculating the odds ratio. The point estimate for the overall effect was 0.49 (95% confidence interval [CI], 0.40–0.61). Twenty-one studies evaluated dexamethasone as a single prophylactic drug. The odds ratio for individual studies is represented by a square on the forest plot with 95% CI of the difference shown as a solid line. Larger-sized square and thicker 95% CI line denote larger sample size. The diamonds represent the pooled estimate and uncertainty for the effects of the 4-mg to 5-mg dexamethasone dose group, the 8-mg to 10-mg dexamethasone dose group, and the overall effect.

Two studies provided 2 comparisons of the 4-mg to 5-mg dexamethasone dose used with a second antiemetic to prevent 24-hour nausea.^{54,93} The studies used 2 mg IV haloperidol⁵⁴ and 1 mg IV granisetron ⁹³ as the first antiemetic. The effect of the 4-mg to 5-mg dexamethasone dose was detected when administered with a second antiemetic (OR, 0.51; 95% CI, 0.32-0.80; NNT, 8.0; 95% CI, 5.3-10.9). Seven studies provided 7 comparisons of the 8-mg to 10-mg dexamethasone dose used with a second antiemetic to prevent 24-hour nausea. 45,50,53,57,70,88,97 The studies used 10 mg $\rm \bar{IV}$ metoclopramide, 45 0.075 mg/kg IV midazolam,⁵⁰ 4 mg IV ondasentron,^{53,97} 1 mg IV granisetron,⁵⁷ 50 mg per os dolasetron,⁷⁰ and 1.25 mg IV droperidol⁸⁸ as the other antiemetic. A significant effect was also detected for the 8-mg to 10-mg dose group when dexamethasone was used with a second antiemetic (OR, 0.44; 95% CI, 0.26-0.75; NNT, 10.4; 95% CI, 5.9-43.4).

The effect of dexamethasone on the 24-hour incidence of nausea was not significantly different for studies performed under general anesthesia (OR, 0.43; 95% CI, 0.35–0.53) compared with studies performed under regional/local anesthesia (OR, 0.38; 95% CI, 0.25–0.60; P = 0.54).

Early (0–6 Hours) Incidence of Nausea

The effect of dexamethasone on the incidence of early nausea by dosing groups is presented in Figure 5. Heterogeneity was low for both dose group comparisons ($I^2 = 0$).

The calculated NNT values for the combined effect of the 4-mg to 5-mg and the 8-mg to 10-mg dose groups were 26.1 (95% CI, 13.1–1000) and 10.3 (95% CI, 7.4–16.6), respectively. The funnel plot did not demonstrate asymmetry for the 4-mg to 5-mg dose group (P = 0.37), but it showed some asymmetry for the 8-mg to 10-mg dose group (P = 0.02).

Three studies examined a 4-mg to 5-mg dexamethasone group used with a second antiemetic.54,72,74 The studies used 2 mg IV haloperidol,⁵⁴ 4 mg IV ondansetron,⁷² and 12.5 mg IV dolasetron⁷⁴ as the other antiemetic. The combined effect did not show a benefit compared with control on the incidence of early nausea (OR, 0.63; 95% CI, 0.34-1.17). Twelve studies provided 11 comparisons of the 8-mg to 10-mg dexamethasone used with a second antiemetic to prevent early nausea.^{39,45,53,57,59,71,72,75,80,88,96,97} The studies used 4 mg IVondansetron,^{39,53,72,80,96,97} 10 mg IV metoclopramide,^{45,59} 1 mg IV granisetron, $^{57}\!40~\mu g/kg$ granisetron, $^{71}\,3$ mg IV granisetron,⁷⁵ and 1.25 mg IV droperidol⁸⁸ as the other antiemetic. When evaluated as combination therapy, the 8-mg to 10-mg dexamethasone dose reduced early nausea (OR, 0.37; 95% CI, 0.23-0.60) but the clinical effect was not significant (NNT, 16.6; 95% CI, 10.1-20.8).

Vomiting Od24 Hours

The effect of dexamethasone on vomiting over 24 hours by dosing groups is presented in Figure 6. Heterogeneity was low for both dose group comparisons ($I^2 = 0$).

The calculated NNT values for the combined effect of the 4-mg to 5-mg and 8-mg to 10-mg dose groups were 7.2 (95% CI, 5.5–10.7) and 6.9 (95% CI, 5.8–8.6), respectively. The

Group by	Study name	Comparison	Outcome		Statis	tics for ea	ach study		Events /	otal	Odds ratio and 95% Cl
Comparison				Odds	Lower	Upper					
				ratio	limit	limit	Z-Value	p-Value	Dexamethasone	Control	
4.5 ma	Chu ref 54	4.5 mg	Vomiting 24 br	0 290	0 134	0.628	-3 141	0.002	12/74	30/75	
4.5 mg	Chu 2 ref 54	4-5 mg	Vomiting 24 hr	0.574	0.231	1.424	-1.198	0.231	9/74	14/72	
4-5 mg	Numezeki ref 63	4-5 mg	Vomiting 24 hr	1 000	0.212	4 709	0.000	1 000	6/30	3/15	
4-5 mg	Wang ref 73	4-5 mg	Vomiting 24 hr	0.331	0.094	1.168	-1.718	0.086	4/39	10/39	
4-5 ma	Wang ref 76	4-5 mg	Vomiting 24 hr	0.299	0.088	1.044	-1.892	0.058	4/38	11/39	
4-5 mg	Trans ref 77	4-5 mg	Vemiting 24 hr	0.279	0.108	1 260	-1 499	0 137	4/38	9/38	
4-5 mg	Wang ref 78	4-5 mg	Vomiting 24 hr	0.225	0.058	0.897	.2 112	0.035	3/39	10/37	
4-6 mg	Les ref 81	4-6 mg	Veniting 24 hr	0.229	0.073	0.711	-2 648	0.011	8 / 43	11/22	
4-5 mg	Huano ref 82	4-5 mg	Vomiting 24 hr	0.205	0.052	0.805	-2.269	0.023	3/39	11/38	
4-5 mg	Shuno-Tai ref 84	4-5 mg	Vomiting 24 hr	0.358	0.085	1.501	-1.405	0.160	4/42	5/22	
4-5 mg	Wang ref 85	4-5 mg	Vomiting 24 hr	0.249	0.053	1.159	.1.772	0.076	3/44	5/22	
4.5 mg	Wang RR	4.5 mg	Vomiting 24 hr	0.229	0.089	1 667	.1 222	0 192	3/43	4/22	
	lackaget ref 93	4-5 mg	Veniting 24 hr	0.693	0.000	1 269	-1.204	0.229	24/120	32/120	
4-5 mg	Sanknegt fer 55	4-0 mg	vonning 24 m	0.403	0.302	0.644	.5 947	0.000	27/873	155 / 571	
4-5 mg	Mathieses ref 40	8-10 mg	Veniting 24 br	0.403	0.200	2 214	-0.452	0.000	7/43	9/45	
5-10 mg	Cistle set 47	8-10 mg	Vomiting 24 nr	0.776	0.201	4 202	-0.402	0.001	7/43 E/DP	3/40	
5-10 mg	Sista ref 47	8-10 mg	Vomiting 24 hr	0.307	0.117	1.203	1.002	0.121	5/30	10 / 34	
s-10 mg	Teo rer 45	a-10 mg	Vomiting 24 hr	0.063	0.209	1.031	-1.027	0.304	8/40	12/40	
s-10 mg	Makhdoom Per SU	8-10 mg	Vomiting 24 nr	0.412	0.087	1.902	-1.118	0.204	3/20	0/20	
s-iu mg	Makhobom 2 ref bu	8-10 mg	vomiting 24 nr	0.4/4	0.039	0.000	-0.069	0.000	1720	2720	
s-10 mg	Fukami ref 51	8-10 mg	vomiting 24 nr	0.121	0.014	1.034	+1.930	0.054	1/40	7740	
s-10 mg	Mathiesen ref 52	8-10 mg	Vomiting 24 hr	0.150	0.031	0.730	-2.338	0.019	2/42	10/40	
5-10 mg	Gautam ref 53	8-10 mg	Vomiting 24 hr	0.382	0.070	2.076	-1.114	0.265	2/47	5/48	
s-10 mg	Ernan ref oo	8-10 mg	Vomiting 24 nr	0.464	0.111	1.940	-1.052	0.293	4/20	7720	
5-10 mg	Kooref 55	8-10 mg	Vomiting 24 hr	0.231	0.061	0.869	-2.167	0.030	7/20	14/20	
8-10 mg	Koc 2 ref 55	8-10 mg	Vomiting 24 hr	0.098	0.011	0.892	-2.062	0.039	1/20	7/20	
8-10 mg	Moussa ref 57	8-10 mg	Vomiting 24 hr	0.444	0.100	1.974	-1.066	0.286	3/30	6/30	
8-10 mg	Biachin ref 58	8-10 mg	Vomiting 24 hr	0.260	0.075	0.906	-2.115	0.034	4/36	12/37	
5-10 mg	Feo ref 65	8-10 mg	Vomiting 24 hr	0.241	0.073	0.795	-2.338	0.019	4/49	14/52	
8-10 mg	Yusek ref 67	8-10 mg	Vomiting 24 hr	0.286	0.077	1.058	-1.875	0.061	6/20	12/20	
5-10 mg	Bisgaard ref 68	8-10 mg	Vomiting 24 hr	0.158	0.032	0.776	-2.273	0.023	2/40	10 / 40	
8-10 mg	Nortoliffe ref 69	8-10 mg	Vomiting 24 hr	0.872	0.312	2.435	-0.262	0.793	17/30	18 / 30	
8-10 mg	Piper ref 70	8-10 mg	Vomiting 24 hr	0.071	0.004	1.280	-1.793	0.073	0 / 75	6/75	
8-10 mg	Tzeng ref 79	8-10 mg	Vomiting 24 hr	0.311	0.075	1.279	-1.619	0.105	3/38	8/37	
8-10 mg	Liu ref 83	8-10 mg	Vomiting 24 hr	0.214	0.055	0.838	-2.214	0.027	3/40	11/40	
8-10 mg	Ping-Heng ref 86	8-10 mg	Vomiting 24 hr	0.766	0.278	2.111	-0.516	0.606	14 / 30	16/30	
8-10 mg	Tzeng ref 88	8-10 mg	Vomiting 24 hr	0.646	0.208	2.030	-0.748	0.454	6/38	9/40	
8-10 mg	Tzeng 2 ref 88	8-10 mg	Vomiting 24 hr	0.708	0.148	3.403	-0.434	0.664	3/37	4/38	
8-10 mg	Wang ref 91	8-10 mg	Vomiting 24 hr	0.201	0.059	0.679	-2.581	0.010	4 / 41	14 / 40	
8-10 mg	Wang ref 92	8-10 mg	Vomiting 24 hr	0.214	0.062	0.732	-2.458	0.014	4 / 40	13/38	
8-10 mg	Wang ref 94	8-10 mg	Vomiting 24 hr	0.168	0.054	0.524	-3.074	0.002	5/38	18 / 38	
8-10 mg	Wang ref 95	8-10 mg	Vomiting 24 hr	0.167	0.033	0.835	-2.179	0.029	2/38	9/38	
8-10 mg	Lopez-Olaondo ref 97	8-10 mg	Vomiting 24 hr	0.599	0.189	1.898	-0.871	0.384	8 / 25	11/25	
8-10 mg	Lopez-Olaondo 2 ref 97	8-10 mg	Vomiting 24 hr	0.132	0.015	1.192	-1.804	0.071	1/25	6/25	
8-10 mg	Mokenzie ref 98	8-10 mg	Vomiting 24 hr	0.358	0.174	0.734	-2.802	0.005	14/91	30/89	
8-10 mg				0.354	0.279	0.450	-8.548	0.000	144 / 1109	316 / 1105	
Overall				0.372	0.309	0.449	-10.393	0.000	231 / 1782	471 / 1676	I I ♥ I I I
											0.01 0.1 1 10 100
											Active Control
											Active

Meta Analysis

Figure 6. Pooled data evaluating the effect of systemic dexamethasone on the 24-hour incidence of vomiting compared with control. Data were evaluated by calculating the odds ratio. The point estimate for the overall effect was 0.37 (95% confidence interval [CI], 0.30–0.44). Thirty-three studies examined dexamethasone used as a single prophylactic drug. The odds ratio for individual studies is represented by a square on the forest plot with 95% CI of the difference shown as a solid line. Larger-sized square and thicker 95% CI line denote larger sample size. The diamonds represent the pooled estimate and uncertainty for the effects of the 4-mg to 5-mg dexamethasone dose group, the 8-mg to 10-mg dexamethasone dose group, and the overall effect.

funnel plot demonstrated some asymmetry (P = 0.04) for the 4-mg to 5-mg dose group and for the 8-mg to 10-mg dose group (P = 0.004). Five studies directly compared the effect of the 8-mg to 10-mg dose group with the 4-mg to 5-mg dose group on the incidence of vomiting over 24 hours.^{63,81,84,85,89} The combined effect showed a wide CI relative to a significant clinical benefit (OR, 0.64; 95% CI, 0.33–1.27).

Two studies evaluated the effect of the 4-mg to 5-mg dexamethasone dose when used with a second antiemetic;^{54,93} both studies did not demonstrate a beneficial effect of the 4-mg to 5-mg dexamethasone compared with the control group (P > 0.05). The studies used 2 mg IV haloperidol⁵⁴ and 1 mg IV granisentron⁹³ as the other antiemetic. Seven studies provided 7 comparisons of 8-mg to 10-mg dexamethasone dose used with a second antiemetic to reduce the incidence of vomiting over 24 hours.50,53,57,70,88,97,98 The effect of the 8-mg to 10-mg dexamethasone on the incidence of vomiting over 24 hours was significant when dexamethasone was examined with a second antiemetic (OR, 0.36; 95% CI, 0.21-0.61; NNT, 11.1; 95% CI, 7.5-21.2).The studies used 0.075 mg IV midazolam,⁵⁰ 4 mg IV ondansetron,^{53,97,98} 1 mg IV granisetron,⁵⁷ 10 mg IV metoclopramide,⁵⁹ 50 mg per os dolasetron,⁷⁰ and 1.25 mg IV droperidol⁸⁸ as the other antiemetic.

The effect of dexamethasone on 24-hour incidence of vomiting was not significantly different for studies performed under general anesthesia (OR, 0.35; 95% CI, 0.17– 0.73) compared with studies performed under regional/ local anesthesia (OR, 0.33; 95% CI, 0.26–0.42; P = 0.17).

Early (0–6 Hours) Vomiting

The effect of dexamethasone on early vomiting by dosing groups is presented in Figure 7. Heterogeneity was low for both dose group comparisons ($l^2 = 0$). The calculated NNT values for the aggregated effect of the 4-mg to 5-mg and the 8-mg to 10-mg dose groups were 17.5 (95% CI, 9.8–90.9) and 16.9 (95% CI, 12.5–25.6), respectively. The funnel plot did not demonstrate asymmetry (P = 0.48) for the 4-mg to 5-mg dose, but it showed some asymmetry for the 8-mg to 10-mg dose (P = 0.04).

Postoperative Need for Rescue Antiemetics (24 Hours)

The effect of dexamethasone on the 24-hour need for postoperative antiemetics by dosing groups is presented in Figure 8. Heterogeneity was low for both dose group comparisons ($I^2 < 10\%$).

The calculated NNT values for the combined effect of the 4-mg to 5-mg and the 8-mg to 10-mg dose groups were



Meta Analysis

Figure 7. Pooled data evaluating the effect of systemic dexamethasone on the early (\leq 6 hours) incidence of vomiting compared with control. Data were evaluated by calculating the odds ratio. The point estimate for the overall effect was 0.41 (95% confidence interval [CI], 0.33–0.53). Nineteen studies examined dexamethasone as a single prophylactic drug. The odds ratio for individual studies is represented by a square on the forest plot with 95% CI of the difference shown as a solid line. Larger-sized square and thicker 95% CI line denote larger sample size. The diamonds represent the pooled estimate and uncertainty for the effects of the 4-mg to 5-mg dexamethasone dose group, the 8-mg to 10-mg dexamethasone dose group, and the overall effect.

Gausse bu	Study arms	Comostions	Orthogra		C tarifa		and an de		Europe / T	atal
Comparison	atuty name	comparison	Outcome		otatis	ius ior ei	aon study	-	Events / I	otai
				Odds ratio	Lower	Upper limit	Z-Value	p-Value	Dexamethasone	Control
4.5 ma	Chu ref 54	4-5 mg	24hr Rescue Antiemetic	0.367	0 183	0.739	-2.810	0.005	18 / 74	35/75
4.5 mg	Chu 2 ref 64	4-5 mg	24hr Rescue Antiemetic	0.469	0.700	1 101	-1 740	0.000	10/74	18/73
4.5 mg	Wass ref 72	4-5 mg	24hr Resource Antiemetic	0.900	0.029	0.769	-7.428	0.015	8/29	16/29
4.5 mg	Wang ref 76	4-5 mg	24hr Rescue Antiemetic	0.218	0.070	0.679	-2.628	0.009	5/38	16/39
15	Tanag and 37	4.5	Othe Descue Antiometic	0.200	0.000	0.070	0.000	0.000	E / 00	14/00
4-0 mg	12eng rer //	4-0 mg	24hr Rescue Antiemetic	0.200	0.082	0.819	-2.300	0.021	0/36	14/38
4-0 mg	Wang ref 78	4-0 mg	24hr Rescue Antiemetic	0.242	0.076	0.763	-2.421	0.015	5/39	14/37
4-5 mg	Lee ref 81	4-5 mg	24hr Rescue Antiemetic	0.286	0.098	0.831	-2.301	0.021	15/45	14/22
4-5 mg	Shung-Tai ref 84	4-5 mg	24hr Rescue Antiemetic	0.290	0.079	1.057	-1.876	0.061	5/42	7/22
4-5 mg	Wang ref 85	4-5 mg	24hr Rescue Antiemetic	0.275	0.075	1.001	-1.959	0.050	5/44	7/22
4-5 mg	Wang 89	4-5 mg	24hr Rescue Antiemetic	0.282	0.077	1.028	-1.918	0.055	5/43	7/22
4-5 mg				0.308	0.221	0.428	-7.022	0.000	79 / 478	148 / 388
8-10 mg	Mathiesen ref 40	8-10 mg	24hr Rescue Antiemetic	1.057	0.358	3.124	0.101	0.920	8 / 43	8 / 45
8-10 mg	Gomez-hernandez ref 41	8-10 mg	24hr Rescue Antiemetic	0.198	0.070	0.558	-3.059	0.002	8/35	21/35
8-10 mg	Sistla ref 47	8-10 mg	24hr Rescue Antiemetic	0.480	0.153	1.509	-1.256	0.209	6/36	10 / 34
8-10 mg	Alghanem ref 46	8-10 mg	24hr Rescue Antiemetic	0.541	0.150	1.954	-0.938	0.348	4/60	7/60
8-10 mg	Yeo ref 49	8-10 mg	24hr Rescue Antiemetic	0.464	0.169	1.276	-1.487	0.137	8 / 40	14 / 40
8-10 mg	Makhdoom ref 50	8-10 mg	24hr Rescue Antiemetic	0.484	0.111	1,940	-1.052	0.293	4/20	7/20
8-10 mg	Makhdoom 2 ref 50	8-10 mg	24hr Rescue Antiemetic	0.474	0.039	5.688	-0.589	0.558	1/20	2/20
8-10 mg	Mathiesen ref 52	8-10 mg	24hr Rescue Antiemetic	0.521	0.200	1.355	-1.337	0.181	10 / 42	15/40
8-10 mg	Gautam ref 53	8-10 mg	24hr Rescue Antiemetic	0.228	0.068	0.749	-2 432	0.015	4/47	14/48
8-10 mg	Nasak-Adam ref 59	8-10 mg	24br Rescue Antiemetic	0.145	0.017	1 268	-1 745	0.081	1/40	6/40
8-10 mg	Nesek-Ariam 2 ref 59	8-10 mg	24hr Rescue Antiemetic	0.100	0.005	1 924	-1.528	0.127	0 / 40	4/40
8-10 mg	We ref 60	8-10 mg	24br Rescue Antiematic	0.615	0.155	2 460	-0.600	0.491	4/20	6/20
8-10 mg	Eas rol 65	8-10 mg	24hr Rescue Antiemetic	0.143	0.049	0.420	-3.643	0.000	5/49	22/62
8.10 mg	Vursek and #7	8-10 mg	24hr Rescue Antiemetic	0.140	0.040	0.420	-0.040	0.000	4/20	11/20
8-10 mg	Tusecier 07	8-10 mg	24hr Rescue Antiemetic	0.200	0.050	0.034	-2.212	0.027	47.20	11/20
8-10 mg	Noncline rer 09	8-10 mg	24nr Rescue Antiemetic	0.757	0.209	2.133	-0.527	0.596	17730	19/30
0-10 mg	Piperter /J	0-10 mg	24nr Rescue Antiemetic	0.412	0.157	1.078	-1.808	0.071	1175	10//5
8-10 mg	Tzeng ref 79	8-10 mg	24hr Rescue Antiemetic	0.173	0.051	0.588	-2.808	0.005	4/38	15/37
8-10 mg	Liu ref 83	8-10 mg	24hr Rescue Antiemetic	0.265	0.090	0.775	-2.428	0.015	6 / 40	16 / 40
8-10 mg				0.368	0.277	0.489	-6.884	0.000	101 / 705	213 / 708
Overall				0.341	0.275	0.423	-9.800	0.000	180 / 1181	361 / 1094

Meta Analysis

Meta Analysis

Figure 8. Pooled data evaluating the effect of systemic dexamethasone on the 24-hour need for rescue antiemetics compared with control. Data were evaluated by calculating the odds ratio. The point estimate for the overall effect was 0.34 (95% confidence interval [CI], 0.27–0.42). Twenty-three studies examined dexamethasone as a single prophylactic drug. The odds ratio for individual studies is represented by a square on the forest plot with 95% CI of the difference shown as a solid line. Larger-sized square and thicker 95% CI line denote larger sample size. The diamonds represent the pooled estimate and uncertainty for the effects of the 4-mg to 5-mg dexamethasone dose group, the 8-mg to 10-mg dexamethasone dose group, and the overall effect.

	study name	Comparison	Outcome		Statis	tics for e	ach study		Events / Te	stal		0	lds ratio and 95% Cl	_
Comparison				Odds ratio	Lower limit	Upper limit	Z-Value	p-Value	Dexamethasone	Control				
4-5 mg	Wu ref 48	4-5 mg	Early Rescue Antiemetics	0.365	0.085	1.576	-1.350	0.177	3/30	7/30	1	+		
4-5 mg	Elhakim ref 72	4-5 mg	Early Rescue Antiemetics	1.000	0.083	11.998	0.000	1.000	2/30	1/15		+		_
4-5 mg	Tzeng ref 77	4-6 mg	Early Rescue Antiemetics	0.488	0.042	5.003	-0.578	0.563	1/38	2/38		_		
4-5 mg	Huang ref 82	4-5 mg	Early Rescue Antiemetics	0.157	0.046	0.531	-2.977	0.003	4/39	16/38			-	
4-5 mg				0.280	0.128	0.654	-2.971	0.003	10 / 137	26/121			-	
8-10 mg	Murphy ref 39	8-10 mg	Early Rescue Antiemetics	0.279	0.107	0.726	-2.615	0.009	7 / 56	20 / 59				
8-10 mg	Erhan ref 55	8-10 mg	Early Rescue Antiemetics	0.091	0.017	0.501	-2.755	0.005	2/20	11/20		_	-	
8-10 mg	Nasek-Adam ref 59	8-10 mg	Early Rescue Antiemetics	0.316	0.031	3.178	-0.978	0.328	1/40	3 / 40		<u> </u>		
8-10 mg	Nasek-Adam 2 ref 59	8-10 mg	Early Rescue Antiemetics	0.132	0.007	2.647	-1.323	0.188	0 / 40	3/40		<u> </u>		
8-10 mg	Chen ref 62	8-10 mg	Early Rescue Antiemetics	0.555	0.327	0.940	-2.190	0.029	24 / 350	41 / 350				
8-10 mg	Piper ref 70	8-10 mg	Early Rescue Antiemetics	0.669	0.240	1.863	-0.769	0.442	7/75	10/75				
8-10 mg	Biswas ref 71	8-10 mg	Early Rescue Antiemetics	0.322	0.033	3.187	-0.969	0.333	1/60	3/60		_	_	
8-10 mg	Thomas ref 80	8-10 mg	Early Rescue Antiemetics	0.265	0.053	1.335	-1.609	0.108	2/58	7/59		_	_	
8-10 mg	Tzeng ref 88	8-10 mg	Early Rescue Antiemetics	0.679	0.263	1.755	-0.799	0.424	11/38	15/40				
8-10 mg	Tzeng 2 ref 88	8-10 mg	Early Rescue Antiemetics	0.989	0.255	3.679	-0.047	0.963	5/37	5/38		· · -	_	
8-10 mg	Wang ref 90	8-10 mg	Early Rescue Antiemetics	0.798	0.254	2.491	-0.392	0.695	12/40	7/20				
8-10 mg	Wang 2 ref 90	8-10 mg	Early Rescue Antiemetics	0.151	0.034	0.670	-2.488	0.013	3 / 40	7/20		_	- 1	
8-10 mg				0.462	0.328	0.651	-4.416	0.000	75/854	132/819		∢		
Overall				0.430	0.314	0.591	-5.219	0.000	85/991	158 / 940		∢	ě I	
											0.01	0.1	1	
												•		
												Activ		nt
												Acuv	e 0	ли

Meta Analysis

Figure 9. Pooled data evaluating the effect of systemic dexamethasone on the early (≤ 6 hours) need of rescue antiemetics compared with control. Data were evaluated by calculating odds ratio. The point estimate for the overall effect was 0.43 (95% confidence interval [CI], 0.31–0.59). Nine studies examined dexamethasone as a single prophylactic drug. The odds ratio for individual studies is represented by a square on the forest plot with 95% CI of the difference shown as a solid line. Larger-sized square and thicker 95% CI line denote larger sample size. The diamonds represent the pooled estimate and uncertainty for the effects of the 4-mg to 5-mg dexamethasone dose group, the 8-mg to 10-mg dexamethasone dose group, and the overall effect.

4.6 (95% CI, 3.6–6.4) and 5.8 (95% CI, 4.5–8.3), respectively. The analysis for the 4-mg to 5-mg and the 8-mg to 10-mg doses were limited by asymmetric funnel plots, indicating the possibility of publication bias (P = 0.01 and P = 0.008, respectively).

Only 1 study evaluated the effect of the 4-mg to 5-mg dexamethasone when used with a second antiemetic (OR, 0.46; 95% CI, 0.20–1.11).⁵⁴ The study used 2 mg IV haloperidol as the other antiemetic.⁵⁴ Four studies provided 4 comparisons for the 8-mg to 10-mg dexamethasone dose group on the 24-hour need for rescue antiemetics.^{50,53,59,70} The effect of dexamethasone on the postoperative need for rescue antiemetics was detected when the 8-mg to 10-mg dexamethasone dose group was examined with a second antiemetic (OR, 0.31; 95% CI, 0.15–0.63; NNT, 8.8; 95% CI, 5.7–19.6). The studies used 0.075 mg IV midazolam,⁵⁰ 4 mg IV ondansetron,⁵³ 10 mg IV metoclopramide,⁵⁹ and 50 mg per os dolasetron⁷⁰ as the other antiemetic.

Early Postoperative Need for Rescue Antiemetics (0–6 Hours)

The effect of dexamethasone on the early (≤ 6 hours) need for postoperative antiemetics by dosing groups is presented in Figure 9. Heterogeneity was low for both dose group comparisons ($I^2 = 0$). The calculated NNT values for the aggregated effect of the 4-mg to 5-mg and the 8-mg to 10-mg dose groups on the need for early rescue antiemetics were 9.4 (95% CI, 4.2–41.6) and 13.3 (95% CI, 8.7–27.0), respectively. The funnel plot did not demonstrate asymmetry for the 4-mg to 5-mg dose group (P = 0.06), but it did for the 8-mg to 10-mg dose group (P = 0.03).

DISCUSSION

Several important findings have emerged from this current meta-analysis on the effect of dexamethasone for the prevention of postoperative nausea and/or vomiting. Different from Karanicolas et al.,³ who detected dose effects of dexamethasone on the incidence of PONV, we did not observe a clinical advantage of the 8-mg to 10-mg systemic dexamethasone dose compared with the 4-mg to 5-mg dose in the prevention of PONV. In addition, when used with a second antiemetic, the 4-mg to 5-mg dose of dexamethasone offered similar clinical benefits as the 8-mg to 10-mg dose, suggesting a lack of clinical advantage for the 8-mg to 10-mg dose. Our results support the SAMBA guidelines– recommended 4-mg to 5-mg dexamethasone dose for the prevention of PONV.¹

There may be several reasons responsible for the different findings between the current meta-analysis and the one previously performed by Karanicolas et al.³ First, Karanicolas et al. arbitrarily compared a 2-mg to 5-mg dose group with an 8-mg to 16-mg dose group, while we based our group analysis on the SAMBA guidelines–recommended dexamethasone dose. Second, we excluded studies performed by the author Yoshitaka Fujii as suggested by Carlisle.⁵ Last, we examined a much larger number of patients, undergoing different surgical procedures, whereas Karanicolas et al.³ only examined patients undergoing laparoscopic cholecystectomy. Nonetheless, we observed less heterogeneity in our comparisons than Karanicolas et al.³ observed in their study, suggesting the generalizability of our findings.

We did not observe differences in the clinical effect of dexamethasone on the prevention of nausea or vomiting when these outcomes were examined separately. In contrast, Tramèr and Walder⁹⁹ reported greater antivomiting than antinausea properties of ondasentron, another commonly used medication to prevent PONV. Nevertheless, it seems that previous comparisons between these individual drugs did not show a significant benefit in favor of a specific drug.¹⁰⁰

Others have performed systematic reviews on the effect of dexamethasone to prevent PONV. Henzi et al.² did not examine the dose-dependent effects of dexamethasone on PONV. Karanicolas et al.³ showed differences in PONV reduction between extreme doses of dexamethasone (2–5 mg vs 8–16 mg) in patients undergoing laparoscopic cholecystectomy. However, some of the doses included in the group comparisons of Karanicolas et al.³ are rarely used by clinical practitioners. Our findings are more generalizable because we included a wide range of surgical procedures, and we performed group comparisons based on common dosages used by clinical practitioners. We also did not detect a clinical benefit of the 8-mg to 10-mg dose compared with the 4-mg to 5-mg dose on the reduction of PONV when dexamethasone was used with a second antiemetic.

Our study is only valid when interpreted according to its limitations. To generalize our findings, we included several types of surgical procedures, allowing the possibility for a greater degree of heterogeneity. However, heterogeneity was low for the vast majority comparisons, which in fact suggests a generalizable effect of dexamethasone to prevent PONV. The funnel plots demonstrated asymmetry for some of the primary analysis involving the 8-mg to 10-mg dose group. The detection of negative studies that were not published due to negative results could decrease the combined effect for the 8-mg to 10-mg dose group in the affected comparisons.¹⁰¹

In summary, we demonstrated that when given as a single drug or when used in combination therapy, 4 mg to 5 mg of dexamethasone seems to have comparable clinical effects on the prevention of PONV as the 8-mg to 10-mg dose. Our findings confirm the recommendation of the SAMBA guide-lines for the prevention of PONV, which favors the 4-mg to 5-mg dexamethasone dose.

DISCLOSURES

Name: Gildasio S. De Oliveira Jr., MD, MSCI.

Contribution: This author helped design and conduct the study, analyze the data, and prepare the manuscript.

Attestation: This author attests to the integrity of the data.

Name: Lucas J. Santana Castro-Alves, MD.

Contribution: This author helped conduct the study and prepare the manuscript.

Name: Shireen Ahmad, MD.

Contribution: This author helped conduct the study and prepare the manuscript.

Name: Mark C. Kendall, MD.

Contribution: This author helped conduct the study and prepare the manuscript.

Name: Robert J. McCarthy, PharmD.

Contribution: This author helped conduct the study, analyze the data, and prepare the manuscript.

Attestation: This author attests to the integrity of the data.

This manuscript was handled by: Peter S. A. Glass, MB, ChB.

REFERENCES

- 1. Gan TJ, Meyer TA, Apfel CC, Chung F, Davis PJ, Habib AS, Hooper VD, Kovac AL, Kranke P, Myles P, Philip BK, Samsa G, Sessler DI, Temo J, Tramèr MR, Vander Kolk C, Watcha M; Society for Ambulatory Anesthesia. Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2007;105:1615–28
- 2. Henzi I, Walder B, Tramèr MR. Dexamethasone for the prevention of postoperative nausea and vomiting: a quantitative systematic review. Anesth Analg 2000;90:186–94

- 3. Karanicolas PJ, Smith SE, Kanbur B, Davies E, Guyatt GH. The impact of prophylactic dexamethasone on nausea and vomiting after laparoscopic cholecystectomy: a systematic review and meta-analysis. Ann Surg 2008;248:751–62
- 4. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009;62:e1–34
- 5. Carlisle JB. The analysis of 169 randomised controlled trials to test data integrity. Anaesthesia. 2012.
- Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12
- 7. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005;5:13
- 8. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88
- Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34
- Arslan M, Demir ME. Prevention of postoperative nausea and vomiting with a small dose of propofol combined with dexamethasone 4 mg or dexamethasone 8 mg in patients undergoing middle ear surgery: a prospective, randomized, double-blind study. Bratisl Lek Listy 2011;112:332–6
- D'souza N, Swami M, Bhagwat S. Comparative study of dexamethasone and ondansetron for prophylaxis of postoperative nausea and vomiting in laparoscopic gynecologic surgery. Int J Gynaecol Obstet 2011;113:124–7
- 12. Pan PH, Lee SC, Harris LC. Antiemetic prophylaxis for postdischarge nausea and vomiting and impact on functional quality of living during recovery in patients with high emetic risks: a prospective, randomized, double-blind comparison of two prophylactic antiemetic regimens. Anesth Analg 2008;107:429–38
- Bano F, Zafar S, Aftab S, Haider S. Dexamethasone plus ondansetron for prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a comparison with dexamethasone alone. J Coll Physicians Surg Pak 2008;18:265–9
- Tiippana E, Bachmann M, Kalso E, Pere P. Effect of paracetamol and coxib with or without dexamethasone after laparoscopic cholecystectomy. Acta Anaesthesiol Scand 2008;52:673–80
- Antonetti M, Kirton O, Bui P, Ademi A, Staff I, Hudson-Civetta JA, Lilly R. The effects of preoperative rofecoxib, metoclopramide, dexamethasone, and ondansetron on postoperative pain and nausea in patients undergoing elective laparoscopic cholecystectomy. Surg Endosc 2007;21:1855–61
- Maddali MM, Mathew J, Fahr J, Zarroug AW. Postoperative nausea and vomiting in diagnostic gynaecological laparoscopic procedures: comparison of the efficacy of the combination of dexamethasone and metoclopramide with that of dexamethasone and ondansetron. J Postgrad Med 2003;49:302–6
- Pueyo FJ, López-Olaondo L, Sanchez-Ledesma MJ, Ortega A, Carrascosa F. Cost-effectiveness of three combinations of antiemetics in the prevention of postoperative nausea and vomiting. Br J Anaesth 2003;91:589–92
- Szarvas S, Chellapuri RS, Harmon DC, Owens J, Murphy D, Shorten GD. A comparison of dexamethasone, ondansetron, and dexamethasone plus ondansetron as prophylactic antiemetic and antipruritic therapy in patients receiving intrathecal morphine for major orthopedic surgery. Anesth Analg 2003;97:259–63
- Sanchez-Ledesma MJ, López-Olaondo L, Pueyo FJ, Carrascosa F, Ortega A. A comparison of three antiemetic combinations for the prevention of postoperative nausea and vomiting. Anesth Analg 2002;95:1590–5
- Kathirvel S, Dash HH, Bhatia A, Subramaniam B, Prakash A, Shenoy S. Effect of prophylactic ondansetron on postoperative nausea and vomiting after elective craniotomy. J Neurosurg Anesthesiol 2001;13:207–12

- 21. Rothenberg DM, McCarthy RJ, Peng CC, Normoyle DA. Nausea and vomiting after dexamethasone versus droperidol following outpatient laparoscopy with a propofol-based general anesthetic. Acta Anaesthesiol Scand 1998;42:637–42
- 22. Feroci F, Rettori M, Borrelli A, Lenzi E, Ottaviano A, Scatizzi M. Dexamethasone prophylaxis before thyroidectomy to reduce postoperative nausea, pain, and vocal dysfunction: a randomized clinical controlled trial. Head Neck 2011;33:840–6
- Leksowski K, Peryga P, Szyca R. Ondansetron, metoclopramid, dexamethason, and their combinations compared for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a prospective randomized study. Surg Endosc 2006;20:878–82
- Ahn JH, Kim MR, Kim KH. Effect of i.v. dexamethasone on postoperative dizziness, nausea and pain during canal wall-up mastoidectomy. Acta Otolaryngol 2005;125:1176–9
 Liu K, Hsu CC, Chia YY. The effect of dose of dexamethasone
- Liu K, Hsu CC, Chia YY. The effect of dose of dexamethasone for antiemesis after major gynecological surgery. Anesth Analg 1999;89:1316–8
- 26. Song JW, Park EY, Lee JG, Park YS, Kang BC, Shim YH. The effect of combining dexamethasone with ondansetron for nausea and vomiting associated with fentanyl-based intravenous patient-controlled analgesia. Anaesthesia 2011;66:263–7
- 27. Nazar CE, Lacassie HJ, López RA, Muñoz HR. Dexamethasone for postoperative nausea and vomiting prophylaxis: effect on glycaemia in obese patients with impaired glucose tolerance. Eur J Anaesthesiol 2009;26:318–21
- Worni M, Schudel HH, Seifert E, Inglin R, Hagemann M, Vorburger SA, Candinas D. Randomized controlled trial on single dose steroid before thyroidectomy for benign disease to improve postoperative nausea, pain, and vocal function. Ann Surg 2008;248:1060–6
- Kirdak T, Yilmazlar A, Cavun S, Ercan I, Yilmazlar T. Does single, low-dose preoperative dexamethasone improve outcomes after colorectal surgery based on an enhanced recovery protocol? Double-blind, randomized clinical trial. Am Surg 2008;74:160–7
- Laiq N, Khan MN, Qureshi FA, Khan S, Jan AS. Dexamethasone as antiemetic during gynaecological laparoscopic surgery. J Coll Physicians Surg Pak 2005;15:778–81
- Al-Shehri AM. Steroidtherapy for post-tonsillectomy symptoms in adults: a randomized, placebo-controlled study. Ann Saudi Med 2004;24:365–7
- Sahjpaul RL, Mahon J, Wiebe S. Dexamethasone for morbidity after subdural electrode insertion–a randomized controlled trial. Can J Neurol Sci 2003;30:340–8
- Halvorsen P, Raeder J, White PF, Almdahl SM, Nordstrand K, Saatvedt K, Veel T. The effect of dexamethasone on side effects after coronary revascularization procedures. Anesth Analg 2003;96:1578–83
- 34. De Oliveira GS Jr, Ahmad S, Fitzgerald PC, Marcus RJ, Altman CS, Panjwani AS, McCarthy RJ. Dose ranging study on the effect of preoperative dexamethasone on postoperative quality of recovery and opioid consumption after ambulatory gynaecological surgery. Br J Anaesth 2011;107:362–71
- 35. Movafegh A, Soroush AR, Navi A, Sadeghi M, Esfehani F, Akbarian-Tefaghi N. The effect of intravenous administration of dexamethasone on postoperative pain, nausea, and vomiting after intrathecal injection of meperidine. Anesth Analg 2007;104:987–9
- 36. Mendes MN, Monteiro Rde S, Martins FA. [Prophylaxis of postoperative nausea and vomiting in morbidly obese patients undergoing laparoscopic gastroplasties: a comparative study among three methods]. Rev Bras Anestesiol 2009;59:570–6
- Kardash KJ, Sarrazin F, Tessler MJ, Velly AM. Single-dose dexamethasone reduces dynamic pain after total hip arthroplasty. Anesth Analg 2008;106:1253–7, table of contents
- McKenzie R, Riley TJ, Tantisira B, Hamilton DL. Effect of propofol for induction and ondansetron with or without dexamethasone for the prevention of nausea and vomiting after major gynecologic surgery. J Clin Anesth 1997;9:15–20
- Murphy GS, Szokol JW, Greenberg SB, Avram MJ, Vender JS, Nisman M, Vaughn J. Preoperative dexamethasone enhances quality of recovery after laparoscopic cholecystectomy:

effect on in-hospital and postdischarge recovery outcomes. Anesthesiology 2011;114:882–90

- Mathiesen O, Jørgensen DG, Hilsted KL, Trolle W, Stjernholm P, Christiansen H, Hjortsø NC, Dahl JB. Pregabalin and dexamethasone improves post-operative pain treatment after tonsillectomy. Acta Anaesthesiol Scand 2011;55:297–305
- 41. Gómez-Hernández J, Orozco-Alatorre AL, Domínguez-Contreras M, Oceguera-Villanueva A, Gómez-Romo S, Alvarez Villaseñor AS, Fuentes-Orozco C, González-Ojeda A. Preoperative dexamethasone reduces postoperative pain, nausea and vomiting following mastectomy for breast cancer. BMC Cancer 2010;10:692
- 42. Sánchez-Rodríguez PE, Fuentes-Orozco C, González-Ojeda A. Effect of dexamethasone on postoperative symptoms in patients undergoing elective laparoscopic cholecystectomy: randomized clinical trial. World J Surg 2010;34:895–900
- Thangaswamy CR, Rewari V, Trikha A, Dehran M, Chandralekha. Dexamethasone before total laparoscopic hysterectomy: a randomized controlled dose-response study. J Anesth 2010;24:24–30
- 44. Mattila K, Kontinen VK, Kalso E, Hynynen MJ. Dexamethasone decreases oxycodone consumption following osteotomy of the first metatarsal bone: a randomized controlled trial in day surgery. Acta Anaesthesiol Scand 2010;54:268–76
- 45. Entezariasl M, Khoshbaten M, Isazadehfar K, Akhavanakbari G. Efficacy of metoclopramide and dexamethasone for postoperative nausea and vomiting: a double-blind clinical trial. East Mediterr Health J 2010;16:300–3
- 46. Alghanem SM, Massad IM, Rashed EM, Abu-Ali HM, Daradkeh SS. Optimization of anesthesia antiemetic measures versus combination therapy using dexamethasone or ondansetron for the prevention of postoperative nausea and vomiting. Surg Endosc 2010;24:353–8
- 47. Sistla S, Rajesh R, Sadasivan J, Kundra P, Sistla S. Does singledose preoperative dexamethasone minimize stress response and improve recovery after laparoscopic cholecystectomy? Surg Laparosc Endosc Percutan Tech 2009;19:506–10
- Wu JI, Lu SF, Chia YY, Yang LC, Fong WP, Tan PH. Sevoflurane with or without antiemetic prophylaxis of dexamethasone in spontaneously breathing patients undergoing outpatient anorectal surgery. J Clin Anesth 2009;21:469–73
- Yeo J, Jung J, Ryu T, Jeon YH, Kim S, Baek W. Antiemetic efficacy of dexamethasone combined with midazolam after middle ear surgery. Otolaryngol Head Neck Surg 2009;141:684–8
- Makhdoom NK, Farid MF. Prophylactic antiemetic effects of midazolam, dexamethasone, and its combination after middle ear surgery. Saudi Med J 2009;30:504–8
- Fukami Y, Terasaki M, Okamoto Y, Sakaguchi K, Murata T, Ohkubo M, Nishimae K. Efficacy of preoperative dexamethasone in patients with laparoscopic cholecystectomy: a prospective randomized double-blind study. J Hepatobiliary Pancreat Surg 2009;16:367–71
- 52. Mathiesen O, Jacobsen LS, Holm HE, Randall S, Adamiec-Malmstroem L, Graungaard BK, Holst PE, Hilsted KL, Dahl JB. Pregabalin and dexamethasone for postoperative pain control: a randomized controlled study in hip arthroplasty. Br J Anaesth 2008;101:535–41
- 53. Gautam B, Shrestha BR, Lama P, Rai S. Antiemetic prophylaxis against postoperative nausea and vomiting with ondansetrondexamethasone combination compared to ondansetron or dexamethasone alone for patients undergoing laparoscopic cholecystectomy. Kathmandu Univ Med J (KUMJ) 2008;6:319–28
- 54. Chu CC, Shieh JP, Tzeng JI, Chen JY, Lee Y, Ho ST, Wang JJ. The prophylactic effect of haloperidol plus dexamethasone on postoperative nausea and vomiting in patients undergoing laparoscopically assisted vaginal hysterectomy. Anesth Analg 2008;106:1402–6
- 55. Erhan Y, Erhan E, Aydede H, Yumus O, Yentur A. Ondansetron, granisetron, and dexamethasone compared for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: A randomized placebo-controlled study. Surg Endosc 2008;22:1487–92

- 56. Koç S, Memis D, Sut N. The preoperative use of gabapentin, dexamethasone, and their combination in varicocele surgery: a randomized controlled trial. Anesth Analg 2007;105:1137–42
- 57. Moussa AA, Oregan PJ. Prevention of postoperative nausea and vomiting in patients undergoing laparoscopic bariatric surgery–granisetron alone vs granisetron combined with dexamethasone/droperidol. Middle East J Anesthesiol 2007;19:357–67
- Bianchin A, De Luca A, Caminiti A. Postoperative vomiting reduction after laparoscopic cholecystectomy with single dose of dexamethasone. Minerva Anestesiol 2007;73:343–6
- Nesek-Adam V, Grizelj-Stojcic E, Rasic Z, Cala Z, Mrsic V, Smiljanic A. Comparison of dexamethasone, metoclopramide, and their combination in the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy. Surg Endosc 2007;21:607–12
- 60. Wu JI, Lo Y, Chia YY, Liu K, Fong WP, Yang LC, Tan PH. Prevention of postoperative nausea and vomiting after intrathecal morphine for Cesarean section: a randomized comparison of dexamethasone, droperidol, and a combination. Int J Obstet Anesth 2007;16:122–7
- 61. Kashmiri ZA, Sheikh Z, Haider S. Injection dexamethasone in preventing postoperative nausea and vomiting: a comparison with placebo in the patients undergoing laparoscopic cholecystectomy. J Coll Physicians Surg Pak 2006;16:689–92
- 62. Chen MS, Hong CL, Chung HS, Tan PP, Tsai CC, Su HH, Wong CH. Dexamethasone effectively reduces postoperative nausea and vomiting in a general surgical adult patient population. Chang Gung Med J 2006;29:175–81
- Numazaki M, Fujii Y. Reduction of postoperative emetic episodes and analgesic requirements with dexamethasone in patients scheduled for dental surgery. J Clin Anesth 2005;17:182–6
- 64. McKean S, Kochilas X, Kelleher R, Dockery M. Use of intravenous steroids at induction of anaesthesia for adult tonsillectomy to reduce post-operative nausea and vomiting and pain: a double-blind randomized controlled trial. Clin Otolaryngol 2006;31:36–40
- 65. Feo CV, Sortini D, Ragazzi R, De Palma M, Liboni A. Randomized clinical trial of the effect of preoperative dexamethasone on nausea and vomiting after laparoscopic cholecystectomy. Br J Surg 2006;93:295–9
- Laiq N, Khan MN, Qureshi FA, Khan S, Jan AS. Dexamethasone as antiemetic during gynaecological laparoscopic surgery. J Coll Physicians Surg Pak 2005;15:778–81
- 67. Yuksek MS, Alici HA, Erdem AF, Cesur M. Comparison of prophylactic anti-emetic effects of ondansetron and dexamethasone in women undergoing day-case gynaecological laparoscopic surgery. J Int Med Res 2003;31:481–8
- Bisgaard T, Klarskov B, Kehlet H, Rosenberg J. Preoperative dexamethasone improves surgical outcome after laparoscopic cholecystectomy: a randomized double-blind placebo-controlled trial. Ann Surg 2003;238:651–60
- Nortcliffe SA, Shah J, Buggy DJ. Prevention of postoperative nausea and vomiting after spinal morphine for Caesarean section: comparison of cyclizine, dexamethasone and placebo. Br J Anaesth 2003;90:665–70
- Piper SN, Triem JG, Röhm KD, Kranke P, Maleck WH, Boldt J. [Prevention of post-operative nausea and vomiting. Randomised comparison of dolasetron versus dolasetron plus dexamethasone]. Anaesthesist 2003;52:120–6
- Biswas BN, Rudra A. Comparison of granisetron and granisetron plus dexamethasone for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy. Acta Anaesthesiol Scand 2003;47:79–83
- 72. Elhakim M, Nafie M, Mahmoud K, Atef A. Dexamethasone 8 mg in combination with ondansetron 4 mg appears to be the optimal dose for the prevention of nausea and vomiting after laparoscopic cholecystectomy. Can J Anaesth 2002;49:922–6
- Wang JJ, Wang PC, Liu YH, Chien CC. Low-dose dexamethasone reduces nausea and vomiting after tympanomastoid surgery: a comparison of tropisetron with saline. Am J Otolaryngol 2002;23:267–71

- 74. Coloma M, White PF, Markowitz SD, Whitten CW, Macaluso AR, Berrisford SB, Thornton KC. Dexamethasone in combination with dolasetron for prophylaxis in the ambulatory setting: effect on outcome after laparoscopic cholecystectomy. Anesthesiology 2002;96:1346–50
- Goksu S, Kocoglu H, Bayazit YA, Yüksek S, Karci Y, Kanlikama M, Oner U. Antiemetic effects of granisetron, droperidol and dexamethasone in otologic surgery. Auris Nasus Larynx 2002;29:253–6
- 76. Wang JJ, Ho ST, Uen YH, Lin MT, Chen KT, Huang JC, Tzeng JI. Small-dose dexamethasone reduces nausea and vomiting after laparoscopic cholecystectomy: a comparison of tropisetron with saline. Anesth Analg 2002;95:229–32
- 77. Tzeng JI, Hsing CH, Chu CC, Chen YH, Wang JJ. Low-dose dexamethasone reduces nausea and vomiting after epidural morphine: a comparison of metoclopramide with saline. J Clin Anesth 2002;14:19–23
- Wang JJ, Tzeng JI, Ho ST, Chen JY, Chu CC, So EC. The prophylactic effect of tropisetron on epidural morphine-related nausea and vomiting: a comparison of dexamethasone with saline. Anesth Analg 2002;94:749–53
- 79. Tzeng JI, Wang JJ, Ho ST, Tang CS, Liu YC, Lee SC. Dexamethasone for prophylaxis of nausea and vomiting after epidural morphine for post-Caesarean section analgesia: comparison of droperidol and saline. Br J Anaesth 2000;85:865–8
- Thomas R, Jones N. Prospective randomized, double-blind comparative study of dexamethasone, ondansetron, and ondansetron plus dexamethasone as prophylactic antiemetic therapy in patients undergoing day-case gynaecological surgery. Br J Anaesth 2001;87:588–92
- Lee Y, Lin PC, Lai HY, Huang SJ, Lin YS, Cheng CR. Prevention of PONV with dexamethasone in female patients undergoing desflurane anesthesia for thyroidectomy. Acta Anaesthesiol Sin 2001;39:151–6
- Huang JC, Shieh JP, Tang CS, Tzeng JI, Chu KS, Wang JJ. Lowdose dexamethasone effectively prevents postoperative nausea and vomiting after ambulatory laparoscopic surgery. Can J Anaesth 2001;48:973–7
- Liu YH, Li MJ, Wang PC, Ho ST, Chang CF, Ho CM, Wang JJ. Use of dexamethasone on the prophylaxis of nausea and vomiting after tympanomastoid surgery. Laryngoscope 2001;111:1271–4
- Ho S, Wang JJ, Tzeng JI, Liu HS, Ger LP, Liaw WJ. Dexamethasone for preventing nausea and vomiting associated with epidural morphine: a dose-ranging study. Anesth Analg 2001;92:745–8
- Wang JJ, Ho ST, Wong CS, Tzeng JI, Liu HS, Ger LP. Dexamethasone prophylaxis of nausea and vomiting after epidural morphine for post-Cesarean analgesia. Can J Anaesth 2001;48:185–90
- Tan PH, Liu K, Peng CH, Yang LC, Lin CR, Lu CY. The effect of dexamethasone on postoperative pain and emesis after intrathecal neostigmine. Anesth Analg 2001;92:228–32
- Coloma M, Duffy LL, White PF, Kendall Tongier W, Huber PJ Jr. Dexamethasone facilitates discharge after outpatient anorectal surgery. Anesth Analg 2001;92:85–8
- 88. Tzeng JI, Tswei TS, Tang CS, Ho ST, Wang JJ. Dexamethasone alone does not prevent postoperative nausea and vomiting in women undergoing dilatation and curettage: a comparison with droperidol and saline. Acta Anaesthesiol Sin 2000;38: 137–42
- 89. Wang JJ, Ho ST, Lee SC, Liu YC, Ho CM. The use of dexamethasone for preventing postoperative nausea and vomiting in females undergoing thyroidectomy: a dose-ranging study. Anesth Analg 2000;91:1404–7
- Wang JJ, Ho ST, Tzeng JI, Tang CS. The effect of timing of dexamethasone administration on its efficacy as a prophylactic antiemetic for postoperative nausea and vomiting. Anesth Analg 2000;91:136–9
- Wang JJ, Ho ST, Liu HS, Ho CM. Prophylactic antiemetic effect of dexamethasone in women undergoing ambulatory laparoscopic surgery. Br J Anaesth 2000;84:459–62
- Wang JJ, Ho ST, Liu YH, Lee SC, Liu YC, Liao YC, Ho CM. Dexamethasone reduces nausea and vomiting after laparoscopic cholecystectomy. Br J Anaesth 1999;83:772–5

- 93. Janknegt R, Pinckaers JW, Rohof MH, Ausems ME, Arbouw ME, van der Velden RW, Brouwers JR. Double-blind comparative study of droperidol, granisetron and granisetron plus dexamethasone as prophylactic anti-emetic therapy in patients undergoing abdominal, gynaecological, breast or oto-laryngological surgery. Anaesthesia 1999;54:1059–68
- 94. Wang JJ, Ho ST, Lee SC, Liu YC, Liu YH, Liao YC. The prophylactic effect of dexamethasone on postoperative nausea and vomiting in women undergoing thyroidectomy: a comparison of droperidol with saline. Anesth Analg 1999;89:200–3
- Wang JJ, Ho ST, Liu YH, Ho CM, Liu K, Chia YY. Dexamethasone decreases epidural morphine-related nausea and vomiting. Anesth Analg 1999;89:117–20
- 96. Rajeeva V, Bhardwaj N, Batra YK, Dhaliwal LK. Comparison of ondansetron with ondansetron and dexamethasone in prevention of PONV in diagnostic laparoscopy. Can J Anaesth 1999;46:40–4

- López-Olaondo L, Carrascosa F, Pueyo FJ, Monedero P, Busto N, Sáez A. Combination of ondansetron and dexamethasone in the prophylaxis of postoperative nausea and vomiting. Br J Anaesth 1996;76:835–40
- 98. McKenzie R, Tantisira B, Karambelkar DJ, Riley TJ, Abdelhady H. Comparison of ondansetron with ondansetron plus dexamethasone in the prevention of postoperative nausea and vomiting. Anesth Analg 1994;79:961–4
- Tramèr MR, Walder B. Efficacy and adverse effects of prophylactic antiemetics during patient-controlled analgesia therapy: a quantitative systematic review. Anesth Analg 1999;88:1354–61
- Carlisle JB, Stevenson CA. Drugs for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev 2006;CD004125
- 101. De Oliveira GS Jr, Chang R, Kendall MC, Fitzgerald PC, McCarthy RJ. Publication bias in the anesthesiology literature. Anesth Analg 2012;114:1042–8